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One of the central motivations behind research of the at-risk mental state is to prevent 
or delay potential transition to psychosis and further progression to schizophrenia, by 
studying the early signs and symptoms without potential confounding effects of 
disease progression and medication. And although the pathophysiological mechanism 
is still poorly understood, it is known that there is a large genetic heritability where a 
combination of different genetic variants sets a predisposition. Therefore, the 
identification of markers that characterise all states of the disease, namely 
schizophrenia, first-episode of psychosis and the at-risk mental state, are a main goal. 
A very robust marker is hippocampal volume reduction in schizophrenia, first-
episode of psychosis and the at-risk mental state. 
In this thesis, I will present research for a deeper characterisation of the hippocampus 
in schizophrenia, first-episode of psychosis and the at-risk mental state and the 
association to genetic risk variants. First, we we found no association of the brain-
derived neurotrophic factor rs6265 polymorphism with the hippocampal volumes 
neither in the original analysis of large cohort of young healthy individuals nor a 
meta-analysis with 5298 healthy subjects in total. Moreover, we detected differences 
between the applied hippocampal measuring techniques, i.e. manual or automated 
segmentation. Second, a meta-analysis of the same association but in 18 independent 
neuropsychiatric patient cohorts including schizophrenia revealed again no 
association. Also, we showed similar hippocampal reductions for Val/Val 
homozygote and Met-carrier patients compared to healthy controls. Third, group-
related comparison of subcortical volumes revealed hippocampal and thalamic 
reductions in at-risk mental state individuals compared to healthy controls. Moreover, 
we found comparable medium effect sizes for both structures assessed with two 
different statistical methods. Fourth, in a cohort of at-risk mental state individuals and 
first-episode of psychosis patients we found a negative association between the 
hippocampal volumes and a polygenic schizophrenia-related risk score. Furthermore, 
a higher polygenic schizophrenia-related risk score was significantly associated with 
a higher probability of an individual being assigned to the first-episode of psychosis 
group compared to the total at-risk mental state group. 
These studies aid a better understanding of hippocampal volume reduction and 
genetic variants associated with schizophrenia, first-episode of psychosis and the at-


























































1.1 Schizophrenia: Epidemiology, clinical symptoms and 
aetiology 
Schizophrenia can be a severe mental disorder affecting around 1% of the population 
worldwide (Lopez and Murray, 1998), while affective- and non-affective psychoses 
account for even 6.3% of global disease burden (“WHO | Global burden of disease,” 
2004). Disease onset is generally in adolescence or early adulthood, although early- 
as well as late-onset schizophrenic forms are known. The risk for male and female is 
comparable, but the average age of onset is 3-4 years later for females (Murray and 
Van Os, 1998) and males tend to be more impaired by negative symptoms with 
poorer social functioning and worse outcome (Fusar-Poli et al., 2012b; Rietschel et 
al., 2015). 
Schizophrenia has a broad range of clinical symptoms, which overlap with other 
neuropsychiatric disorders. The symptoms are classified into positive and negative 
symptoms according to DSM-5 and ICD-10. Positive symptoms comprise paranoia, 
delusion, hallucination, suspiciousness and conceptual disorganization, while 
negative symptoms include blunted effect, emotional and social withdrawal, 
disorganized speech and apathy. The disease can be additionally characterized by 
cognitive deficits. The symptoms are highly heterogeneous between patients, though 
positive symptoms generally appear in an episodic form whereas negative symptoms 
are more persistent over time (Mueser and McGurk, 2004). 
Twin and family studies reported a strong genetic component of schizophrenia. Twin 
studies revealed a heritability of up to 80% (Cannon TD et al., 1998; Cardno AG et 
al., 1999; Farmer et al., 1987; Sullivan et al., 2003), whereas environmental variance 
accounted for 11% (Sullivan et al., 2003). Moreover, first degree relatives have a 
higher lifetime prevalence of 6-46% compared to the general population and second 
degree relatives have still a 2-4% higher risk for developing schizophrenia (Agerbo et 
al., 2015; Kendler et al., 1993, 1985; Lichtenstein et al., 2009). This high percentage 
of heritability points towards a complex polygenic disorder of non-mendelian 
inheritance rather than a single causal genetic factor (McGue et al., 1983). Besides 
genetic predisposition, several lines of evidence also suggest environmental trigger-
factors increase the risk for schizophrenia. Possible environmental stressors are 
obstetric complications, place of birth, migration, stressful life events and cannabis 
consumption (Cannon et al., 2002; van Os et al., 2010). The observed clinical 




of environmental factors resulted in two different concepts for schizophrenia origin. 
The first is the neurodegenerative concept from the early days of Kraepelin 
(Kraepelin and Robertson, 1919) and the second is the neurodevelopmental concept 
proposed first by Weinberger and also Murray (Murray and Lewis, 1987; 
Weinberger, 1987). Although this is still a matter of debate, both take into account 
that critical neuronal circuits are under plastic rearrangement especially before 
adulthood and that impairments in these circuits, e.g. altered synaptic plasticity, 
might be a cause of a long-lasting disturbance. Examining the underlying 
neurobiology of schizophrenia without confounding effects such as medication, 
disease progression or hospitalization, early clinical detection and intervention 
assesses the stages before the onset of schizophrenia, the first-episode of psychosis 
(FEP) and the at-risk mental state (ARMS). 
 
1.2 First-episode psychosis and at-risk mental state 
FEP patients experience psychotic symptoms for the first time. They fulfil the criteria 
for acute psychotic disorder according to ICD-10 or DSM-5 but not for schizophrenia 
and meet the operational criteria according to Breitborde et al. (Breitborde et al., 
2009; Kahn and Sommer, 2015). The most common treatments for FEP patients are 
psychological therapy (e.g. cognitive behavioural therapy) and pharmacological 
treatment (mainly antipsychotics and antidepressants). While all antipsychotics 
essentially interact with the dopamine receptor (Seeman, 2001), positive symptoms 
are thereby improved, but they have a limited impact on negative symptoms (Fusar-
Poli et al., 2015; Leucht et al., 2009) and cognitive deficits (Keefe et al., 2007). 
Moreover, around 30% of patients are treatment-resistant to antipsychotics (Meltzer, 
1997). 
The ARMS is described on the diagnostic level by early signs and symptoms that 
precede the characteristics of an acute FEP (Fusar-Poli P et al., 2013). In more detail, 
the ARMS is characterized by attenuated psychotic symptoms and a decline in social 
and occupational functioning, corresponding to the criteria by Yung et al. (Riecher-
Rössler et al., 2009, 2007; Yung et al., 2005). In comparison to genetic high-risk 
individuals these clinical high-risk individuals already have subtle symptoms and 
might not have relatives with schizophrenia. The ARMS might lead to an enhanced 
risk for psychiatric diseases, especially for schizophrenia. Around 30% of the 
heterogeneous ARMS group undergo transition to psychosis in the first two years and 




schizophrenia (Fusar-Poli et al., 2013). In contrast, the long-term outcome of ARMS 
individuals that do not develop psychosis is not clear. Most of them may continue in 
the ARMS while few will remit spontaneously (Brandizzi et al., 2015; Simon et al., 
2013; Ziermans et al., 2011). A central motivation of high-risk research is to prevent 
or delay transition to psychosis by early intervention (Clark et al., 2015; van der Gaag 
et al., 2013). However, solely on clinical symptoms it is not possible to identify those 
ARMS individuals with subsequent transition to psychosis. Therefore, the 
identification of risk markers such as structural and functional brain alterations, 
neurocognitive, environmental and genetic markers might help to identify the ARMS 
individuals who undergo subsequent transition to psychosis.  
 
1.3 Endophenotype concept in schizophrenia: Neuroimaging 
The endophenotype approach was created to unravel the genetic architecture of 
psychiatric diseases by using easier measurable characteristics that have a closer 
relationship to the biological processes than diagnostic criteria (Flint and Munafò, 
2007; Gottesman and Shields, 1973; Preston and Weinberger, 2005). The definition 
of Gottesman and Gould (Gottesman and Gould, 2003) states that the biological 
marker is associated with the heritable disease, is present also when the disease is not 
(primarily state-independent), co-segregates with the psychiatric illness and can also 
be observed at a higher rate in healthy siblings of patients than in the population. An 
appealing endophenotype is that of neuroimaging, with which the effect of candidate 
risk genes can be observed in fewer patients using structural and/or functional 
magnetic resonance imaging (MRI) findings compared to clinical symptoms (Meyer-
Lindenberg and Weinberger, 2006; Rose and Donohoe, 2013).  
The identification of brain structural alterations revealed several reproducible results 
for ARMS and FEP in comparison to healthy controls (HC). Namely, FEP patients 
and even ARMS individuals show similar grey matter volume reduction of medial 
frontal gyrus, anterior cingulate, superior temporal gyrus, insula and medial temporal 
lobe compared to HC (Fusar-Poli et al., 2011; Radua et al., 2012; Shepherd et al., 
2012; Steen et al., 2006; Vita et al., 2012, 2006).  
A very robust marker of schizophrenia, FEP and the ARMS is volumetric 
hippocampal reduction (Adriano et al., 2012; Fusar-Poli et al., 2012c, 2011; Haijma 
et al., 2013; Shepherd et al., 2012; Steen et al., 2006; Vita et al., 2006; Wright et al., 
2000). However, results are inconsistent on the differences in hippocampal volume 




of future transition to psychosis (Fusar-Poli et al., 2014, 2012c; Smieskova et al., 
2010). Additionally, moderate genetic heritability of the hippocampal volumes was 
shown in large extended families affected with schizophrenia (Roalf et al., 2015), 
making it an acceptable endophenotype. 
The hippocampus is of special interest as it is involved in cognitive functioning 
(Wixted and Squire, 2011) which is impaired in schizophrenia and already to some 
extent in the ARMS (Bora and Murray, 2014; Fusar-Poli et al., 2012b; Mesholam-
Gately et al., 2009; Savla et al., 2013). Therefore, hippocampal activation during 
working memory processing are widely conducted in ARMS individuals, FEP and 
schizophrenia patients revealing neurofunctional alterations (Fusar-Poli et al., 2007; 
Henseler et al., 2009; Kraguljac et al., 2013; Radua et al., 2012; Yan et al., 2015). 
In addition, the memory network, including the hippocampus and the prefrontal 
cortex (Smith and Jonides, 1999), is of interest, but until now not many studies 
conducted functional or structural connectivity analyses in schizophrenia (Benetti et 
al., 2009; Ellison-Wright and Bullmore, 2009; Harms et al., 2013; Henseler et al., 
2010; Meyer-Lindenberg et al., 2005; Samartzis et al., 2014; Wolf et al., 2009). 
However, already in 1995 Friton and Frith proposed the disconnectivity hypothesis of 
schizophrenia with altered connections between temporal and prefrontal cortices 
(Friston and Frith, 1995). 
1.4 Single nucleotide polymorphisms and polygenic 
schizophrenia-related risk score 
The high heritability suggests a strong genetic element in the development of 
schizophrenia with a multifactorial polygenic model as mode of transmission (McGue 
et al., 1983). This is suggestive of many thousands of common genetic variants with 
weak effect that in combination with specific individual environmental factors can 
induce psychosis (International Schizophrenia Consortium et al., 2009; Lee et al., 
2012). Rare genetic variants exist that are highly penetrant and associated with a high 
risk for schizophrenia, like the 22q11.2 deletion syndrome (Bassett and Chow, 1999) 
but they are not frequent in the common population. The common genetic marker, 
single nucleotide polymorphisms (SNPs), is a single base pair substitution, occurring 
about every 300 base pairs in the genome with a minor allele frequency of more than 
1% in the common population. Although individual effects of SNP on the genetic risk 
for schizophrenia was found to be small, it was estimated that 23% of variation in 




this variation attributed to common causal variants (Lee et al., 2012; Ripke et al., 
2013). 
At first, SNPs within chromosomal regions identified though linkage studies or 
within genes of causal biological reasoning, such as target sites of antipsychotic 
medication, were further investigated in association studies, to assess an 
overrepresentation of one allele in patients that might indicate a risk for the disease 
(McGuffin et al., 2003). Multiple susceptibility loci that co-segregate with the disease 
were repeatedly investigated leaving contradictory findings (Allen et al., 2008) where 
most of the early candidates disappeared again (Crow, 2011). But through genome-
wide association studies (GWAS) the examination of hundreds of thousands of SNPs 
was made possible (International Schizophrenia Consortium et al., 2009; O’Donovan 
et al., 2008; Psychosis Endophenotypes International Consortium et al., 2014; 
Rietschel et al., 2012; Ripke et al., 2013; Schizophrenia Psychiatric Genome-Wide 
Association Study (GWAS) Consortium, 2011; Schizophrenia Working Group of the 
Psychiatric Genomics Consortium, 2014; Shi et al., 2009). This allows the 
hypothesis-free identification of risk variants covering the entire genome and the 
utilization of large sample sizes achieved by international collaboration and the 
formation of consortia. The newest and largest of these GWAS, investigating putative 
risk variants in nearly 37’000 schizophrenia patients and more than 113’000 HC, 
identified 108 schizophrenia-associated genetic loci, explaining up to 3.4% of the 
phenotypic variance in case-control studies (Schizophrenia Working Group of the 
Psychiatric Genomics Consortium, 2014).  
 
1.5 Imaging genetics 
1.5.1 Candidate single nucleotide polymorphisms 
The association of identified neuroimaging markers with causal or newly identified 
genetic variants, i.e. imaging genetics, generated a long list of candidate SNPs 
associated to schizophrenia. However, studies exploring the association of only one 
single or few SNPs with brain structures or function in schizophrenia and FEP 
patients, ARMS individuals and HC mostly generated few replication studies which 
in turn produced contradictory results (e.g. Review by(Meyer-Lindenberg, 2010; 
Rasetti and Weinberger, 2011; van Haren et al., 2008)).  
The association most investigated in HC and across neuropsychiatric disorders is that 




hippocampal volumes. BDNF is highly expressed in the hippocampus where it plays 
an important role in adult neurogenesis and is thought to be involved in learning- and 
memory-dependent processes (Cunha et al., 2010). The SNP results in a substitution 
of valine (Val) to methionine (Met) at codon 66 of the BDNF gene and leads to 
improper BDNF sorting through the activity-dependent secretion pathway (Chen et 
al., 2004; Egan et al., 2003). 
In order to summarize and further evaluate such putative associations meta-analyses 
are a very important tool (Munafò and Flint, 2004).  
 
1.5.2 Polygenic schizophrenia-related risk score 
Although single SNP analyses illustrate the potential benefit of imaging genetics, 
they have to be treated with caution since the analysis of one single SNP neglects the 
multifactorial nature of schizophrenia. Therefore, it can only account for a very small 
amount of genetic risk for susceptibility to the disorder. However, the accumulation 
of the estimated cumulative genomic risk for schizophrenia can be incorporated into a 
polygenic schizophrenia-related risk score (PSRS). The PSRS can overcome the 
small risk related to an individual SNP by explaining a slightly larger genetic 
predisposition for schizophrenia using the predictive power of GWAS analyses.  
Studies applying the PSRS approach showed a significantly negative association with 
total brain volume (Terwisscha van Scheltinga et al., 2013) and especially white 
matter volume (Oertel-Knöchel et al., 2015; Terwisscha van Scheltinga et al., 2013) 
in different cohorts of schizophrenia patients, their relatives and/or HC. 
Unfortunately, another study failed to replicate these findings in an independent 
cohort of HC (Papiol et al., 2014). Moreover, a PSRS of 41 SNPs was positively 
associated with dorsolateral prefrontal cortex inefficiency during a working memory 
task in schizophrenia patients and HC (Walton et al., 2013). The same research group 
could replicate their findings with a larger set of nominally significant SNPs and in a 
bigger cohort of schizophrenia patients and HC (Walton et al., 2014). However, none 
of them investigated the association of a PSRS with brain volume in ARMS 
individuals and/or FEP patients. And although a GWAS analysis identified single 
SNPs linked to hippocampal volume in HC (Hibar et al., 2015), no study to date 






2 Aim and own contribution 
The aim of this doctoral thesis was to identify genetic and neuroimaging markers that 
might indicate a predisposition for vulnerability to psychosis. The schizophrenia-
associated candidate variants might have a measurable impact on brain regions 
known to differ in ARMS individuals and FEP patients. Therefore, we wanted to 
investigate the neurobiology of vulnerability to psychosis by the association of 
specific genetic variants with structural MRI measures implicated in the susceptibility 
for schizophrenia.  
The role of the most investigated endophenotype in schizophrenia, FEP and ARMS –
hippocampal volume reduction in the developing disorder in association with genetic 
markers – was chosen to obtain a better understanding of the genetic risk for 
schizophrenia especially for ARMS individuals and FEP patients. 
First, in collaboration with the research groups of Prof. Andreas Papassotiropulos and 
Prof. Dominique De Quervain, we investigated the association of BDNF rs6265 
polymorphism and hippocampal volume in their large HC sample. Furthermore, I 
performed a meta-analysis including these new data and 27 original publications to 
elaborate the basis of this aspect in health.  
Second, I performed a meta-analysis of this association in 1695 neuropsychiatric 
patients with either schizophrenia, bipolar disorder, major depressive disorder or 
anxiety disorder.  
Third, I analyzed differences of subcortical volumes, including the hippocampus, 
between ARMS and HC in a cohort from Basel and Zurich. 
Fourth, I applied the PSRS approach in association with hippocampal volume, on our 
cohort of ARMS individuals and FEP patients.  
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a b s t r a c t
Background: The brain-derived neurotrophic factor (BDNF) Val66Met polymorphism (refSNP Cluster
Report: rs6265) is a common and functionally relevant single nucleotide polymorphism (SNP). The gene
itself, as well as the SNP rs6265, have been implicated in hippocampal learning and memory. However,
imaging genetic studies have produced controversial results about the impact of this SNP onhippocampal
volumes in healthy subjects.
Methods:We examined the association between the rs6265 polymorphism and hippocampal volume in
643 healthy young subjects using automatic segmentation and subsequently included these data in a
meta-analysis based on published studies with 5298 healthy subjects in total.
Results:Wefoundno significant associationbetweenSNP rs6265 andhippocampal volumes in our sample
(g=0.05, p=0.58). The meta-analysis revealed a small, albeit significant difference in hippocampal vol-
umes between genotype groups, such that Met-carriers had slightly smaller hippocampal volumes than
Val/Val homozygotes (g=0.09, p=0.04), an association that was only evident when manual (g=0.22,
p=0.01) but not automatic tracing approaches (g=0.04, p=0.38) were used. Studies using manual trac-
ing showed evidence for publication bias and a significant decrease in effect size over the years with
increasing sample sizes.
Conclusions: This study does not support the association between SNP rs6265 and hippocampal volume
in healthy individuals. The weakly significant effect observed in the meta-analysis is mainly driven by
studies with small sample sizes. In contrast, our original data and the meta-analysis of automatically
segmented hippocampal volumes, which was based on studies with large samples sizes, revealed no
significant genotype effect. Thus, meta-analyses of the association between rs6265 and hippocampal
volumes should consider possible biases related to measuring technique and sample size.
© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).
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1. Introduction
Brain-derived neurotrophic factor (BDNF) – a member of the
nerve growth factor family – plays an important role in neurogen-
esis and is implicated in several molecular processes in the central
nervous system (Barde et al., 1982; Lu and Gottschalk, 2000; Park
and Poo, 2013). BDNF is highly expressed in the hippocampus, a key
region for adult neurogenesis (De Quervain and Papassotiropoulos,
2006; Milner et al., 1998), and is thought to be involved in learning
and memory (Cunha et al., 2010). Pro-BDNF can induce apoptosis,
whilemature BDNF predominantlymediates cell survival and neu-
ronal differentiation (Panget al., 2004;Korte et al., 1995; Pastalkova
et al., 2006). The single nucleotide polymorphism (SNP) rs6265
at codon 66 of the BDNF gene predicts a valine (Val) to methi-
onine (Met) substitution in the pro-region of the protein, which
is important for proper BDNF sorting. The Val66Met substitution
has been investigated in a transgenic mouse model of defective
BDNF secretion in hippocampal neurons (Chen et al., 2004; Egan
et al., 2003). BDNF Met/Met mice have smaller hippocampal vol-
umes, less dendritic arbor complexity of hippocampal neurons
and impaired synaptic plasticity, as indicated by a decrease in
NMDA-receptor-dependent long-term depression and long-term
potentiation (Chen et al., 2006; Ninan et al., 2010).
Defects in synaptic plasticity and long-term potentiation, core
mechanismsofhippocampus-dependent learning andmemory, are
thought to underlie – at least in part – neurocognitive impairments
in a broad spectrum of neuropsychiatric disorders (Fusar-Poli
et al., 2012; Lu et al., 2013). Another characteristic of neuropsychi-
atric disorders, such as schizophrenia, bipolar disorder, depression,
post-traumatic stress disorders and personality disorders, is the
reduction in hippocampal volume (Geuze et al., 2005; Smieskova
et al., 2010; Walter et al., 2012). It is still not clear to what extent
these hippocampal volume abnormalities are driven by genetic
liability (Sullivan et al., 2003). One putative genetic risk factor
of these alterations might be the BDNF polymorphism described
above (Boulle et al., 2012; Frielingsdorf et al., 2010). The effect
of this polymorphism has often been studied in healthy subjects,
because in ahealthypopulation, changes in brain volumes are inde-
pendent of effects of illness or medication, and of disease-related
genetic risk factors (Fusar-Poli et al., 2013; Smieskova et al., 2009).
To date findings from structural magnetic resonance imag-
ing (sMRI) studies investigating genotype-dependent association
of rs6265 SNP on hippocampal volumes are inconsistent. While
three recent meta-analyses report that Met-carriers have smaller
hippocampal volumes than Val/Val homozygotes (Hajek et al.,
2012; Kambeitz et al., 2012; Molendijk et al., 2012a), the relation
between rs6265 and hippocampal volumes is confounded by sev-
eral problems: Firstly, two of these studies (Kambeitz et al., 2012;
Molendijk et al., 2012a) included a variety of neurocognitive disor-
ders, suggesting that hippocampal volumeswere probably affected
by burden of illness, medication or comorbid conditions and were
not necessarily related to the SNP per se. Secondly, all of these
meta-analyses incorporated studies with children/adolescents and
elderly subjects. This can be critical, as hippocampal volumes
undergo age-related changes (Karnik et al., 2010; Walhovd et al.,
2011; Goodro et al., 2012). Finally, although one of the previous
meta-analyses focuses exclusively on healthy subjects (Hajek et al.,
2012), the analysis in this study was restricted to manual tracing
of hippocampal volumes without considering automatic measure-
ment techniques.
The present study aimed to control for these confounding fac-
tors. First, we assessed the association between the BDNF rs6265
polymorphism and hippocampal volumes using the automated
tracing technique in 643 healthy young volunteers. Because the
effect size of this association is known to be small (Kambeitz et al.,
2012; Molendijk et al., 2012a), we then increased statistical power
by means of meta-analytic techniques (Kim-Cohen et al., 2006;
Munafò et al., 2009; Brandys et al., 2011).We therefore performed a
systematic review of the hippocampal volumes in healthy subjects
genotyped for SNP rs6265 and combined these data with our origi-
nal results in ameta-analysis. Additionally, we examined the effect
of potential moderators such as measuring technique, MR mag-
netic field strength, age, gender, ethnicity, Val/Met ratio, sample
size, quality rating, hippocampal volumes normalized to intracra-
nial volume (ICV), and publication year.
2. Material and methods
2.1. Original data of 643 healthy subjects
2.1.1. Participants
We recruited 643 healthy young subjects (383 women;
age range 18–35 years, mean age± standard deviation (SD)
22.87±3.22). Participants filled in a self-rating questionnaire con-
cerning their health status, medication, and drug consumption.
All included subjects were free of any physical, neurological or
psychiatric illness, and were taking no medication. 87% of the sub-
jects were students and 91% were right-handed (see Table 1). The
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Table 1
Overview of included subjects.




Statistics p-Value Effect size*
Age [mean± SD] 22.75±3.22 413 23.10±3.23 230 F=1.72 df =1 0.19 0.003
Sex
Women 254 129 x2 = 1.80 0.18 0.053
Men 159 101 df =1
Profession
In education 361 198 x2 = 0.69 0.71 0.033
Working 35 24 df =2
Not in education and without job 12 6
Handedness
Right 376 210 x2 = 0.01 0.91 0.004
Left 37 20 df =1
* Partial eta (!2) is reported for age differences, whereas Cramers V is indicated for sex, profession and handedness differences.
Written informed consent was obtained from all subjects prior to
participation.
2.1.2. Genotyping
DNA was extracted from saliva samples collected with the Ora-
gene DNA sample collection kit using standard procedures (DNA
Genotek Inc., Ontario, Canada). DNA sampleswereprocessedon the
Affymetrix® Genome-Wide Human SNP Array 6.0. in one central-
ized microarray facility. rs6265 (refSNP Cluster Report: rs6265) is
representedon thearray (AFFY|SNP A-2038925).Generationof SNP
calls and arrayquality controlwereperformedusing theAffymetrix
GenotypingConsole Software3.0 (Affymetrix Inc.). According to the
manufacturer’s recommendation, contrast quality control (QC)was
chosenasQCmetric, using thedefault valueof 0.4. All samplespass-
ing QC criteria were subsequently genotyped using the Birdseed
(v2) algorithm. Genotypic outliers were identified using Bayesian
clustering algorithm (Bellenguez et al., 2012) and excluded (for
more details see supplementary material).
2.1.3. Image acquisition and extraction of hippocampal volumes
We acquired an anatomical sequence with a radio-frequency
pulses and rapid gradient-echo (MPRAGE) sequence. For this
sequence, we used the following acquisition parameters: TE
(echo time) =3.37ms, FOV (field of view) =25.6 cm, acquisition
matrix =256×256×176, voxel size: 1mm×1mm×1mm. Using
a midsaggital scout image, 176 contiguous axial slices were placed
along the anterior–posterior commissure (AC–PC) plane covering
the entire brain with a TR=2000ms (" =8 degrees).
Segmentations of cortical and subcortical structures were
retrieved from FreeSurfer 4.5 and labeling was based on the
Desikan–Killiany Atlas (Desikan et al., 2006). We extracted raw
volumes for both hippocampi for n=805 subjects. Left and right
hippocampal volumes were corrected separately for ICV, age, sex
and differences due to software and gradient updates by using the
z-transformed residuals of a linear regression. Afterwards we did
a separate outlier-control for both hippocampal sides (mean±3.5
SD). For all subjects with complete dataset, we then calculated the
correctedmeanvalueof bothhippocampal volumes. For a subgroup
of n=643 subjectswehad additional genetic information regarding
BDNF genotype. The corrected volumetric data of these subjects
were included in all further analyses.
2.1.4. Association analysis
For the genetic association analysis, we used the WG-Permer
software (www.wg-permer.org), with analysis of variance for
quantitative phenotypes. This software corrects nominal p-values
for multiple testing on a permutation-based procedure according
to Westfall and Young (Westfall, 1993).
One-way analyses of variance (ANOVA) and chi-square tests
were used to test for differences between genotype groups of age,
sex, profession and handedness. These statistical analyses were
performedwith SPSS (IBMSPSS Statistics, Version 20, 2011). Values
are presented as mean± SD (see Table 1).
2.2. Meta-analysis
2.2.1. Literature search and inclusion criteria
Electronic searcheswere conducted using PubMed and Embase,
considering all publications until the end of December 2012 with
the following search terms: “BDNF Val66Met” AND “MRI” and
“rs6265” AND “MRI”. Additionally, a retrospective search was
carried out on the reference lists of the included articles. This
resulted in 86 publications, for which the abstracts were screened
(more information is presented in Fig. 1). In this meta-analysis,
we included healthy groups only. Firstly, we extracted studies
addressing the relation between hippocampal volumes and the
SNP. Secondly, the papers were filtered according to the following
criteria: (a) published in a peer-reviewed journal, (b) reporting a
relation between the SNP rs6265 and sMRI, (c) showing hippocam-
pal data. A total of 27 publications met these criteria, whereof
from one recent genome-wide association study (GWAS) data of
5 cohorts were obtained (Stein et al., 2012). Altogether a total
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of 32 samples, 31 previously published and our own data, were
included in this meta-analysis. Criteria for exclusion were: mean
age of participants (<15 or >65 years), not clearly defined healthy
control group, overlapping datasets, and only left or only right
hippocampal volume reported. The authors were contacted when
information essential for the calculation of effect sizes was miss-
ing. Bothmeasuring techniques, i.e. automated andmanual tracing,
were included.We followed the ‘Preferred Reporting Items for Sys-
tematic Reviews and Meta-Analyses’ (PRISMA) guidelines (Moher
et al., 2010).
2.2.2. Data extraction
The following variableswere extracted: First author name, pub-
lication year, number of independent samples per study. For each
independent sample, we extracted sample size of genotype sub-
groups, ethnicity, gender, mean age of sample, Hardy–Weinberg
equilibrium (HWE; calculated, when not reported), genotyping
method, structuralMRImeasurement technique, directionof effect,
field strength of MR scanner, mean hippocampal volumes and
standard deviation, t-statistic, F-statistic and p-values per geno-
type, and whether the hippocampal volumes were normalized to
ICV. To sustain statistical independence, one single effect size per
sample was used for this meta-analysis.
2.2.3. Quality assessment
Using an 11-item checklist adapted from (Karg et al., 2011) the
quality of the included studies was evaluated. In detail, the crite-
ria were: (1) Funding – role in analysis and interpretation of data,
(2) Sample size, (3) Clear inclusion criteria for participants, (4)
Reported allele distribution, (5) Ethnicity assessed, (6) Ifmixed eth-
nicity:discussionofproblems, (7) IQ/educational level available, (8)
Inter- and intrarater reliability, (9) Report of HWE, (10) Sample in
HWE and (11) Additional descriptive data including age, gender,
genotyping method, magnetic field strength of scanner. For each
category 0, 1 or 2 points were given. Finally, the included studies
were rated according to the sum of the points and characterized as
high (above 80% of the maximal sum of points), moderately high
(60–79%), moderate (40–59%), moderately low (20–39%), and low
quality studies (below 19%) (for more details see supplementary
tables S1 and S2).
2.2.4. Data analysis
Data were entered into an electronic database and quantitative
meta-analysis was performed using the R 2.15.2 software (R Core
Team, 2012). The effect size was calculated using Hedge’s g, which
provides an unbiased standardized mean difference that incorpo-
rates a correction for small sample sizes (Lipsey andWilson, 2000).
Hedge’s gvalues above0.2, 0.5 and0.8 correspond to small,medium
and large effect sizes respectively. Hedge’s g was calculated using
data of mean hippocampal volumes, standard deviations and sam-
ple sizes. Where these data were not available, we employed the
t-statistic, F-statistic or p-values, together with the correspond-
ing sample sizes. A positive value of the effect size reflected larger
hippocampal volumes in theVal/Val homozygotes than for theMet-
carriers of the SNP rs6265. We employed a random-effects model
with the DerSimonian-Laird estimator using the metafor package
(DerSimonian and Laird, 1986; Wolfgang Viechtbauer, 2010). The
random-effectsmodel showsmore flexibility with respect to effect
size variability between studies and study populations (Cooper
et al., 2009), as it incorporates the between-study variance !2. And
in case of high between-study heterogeneity, the random-effects
model compared to the fixed-effects model is the model of choice
(Ioannidis et al., 2007).
Cochran’s Q test was then used to calculate between-group het-
erogeneity; the magnitude of heterogeneity was assessed by I2
(Higgins andThompson, 2002). I2 is an estimate of variability across
studies based on heterogeneity rather than chance, ranging from 0
to 100%. Values above 25%, 50% and 75% corresponded to low,mod-
erate and high heterogeneity respectively (Higgins and Thompson,
2002). Furthermore, potential publication bias was investigated by
funnel plot asymmetry and Egger’s regression test (Egger et al.,
1997). In case of a bias, “the trim and fill” method was used sub-
sequently to identify and correct for publication bias detected by
an asymmetric funnel plot (Duval and Tweedie, 2000). A series of
meta-regression analyses was carried out to assess the impact of
possibly moderating study design characteristics such as publica-
tion year, age of participants, gender ratio, ethnicity, Val/Met ratio,
sample size, quality rating, magnetic field strength, hippocampal
volumes normalized to intracranial volume and applied hippocam-
pal measuring techniques. Most studies used a dominant allele
approach, but two studies reported an additive allele comparison
(Agartz et al., 2006; Gruber et al., 2012). Nevertheless, these were
treated equivalently in this analysis.
3. Results
3.1. Association analysis of 643 healthy subjects
Of the 643 subjects, 413 were homozygous for the Val allele,
204 were heterozygous Val/Met, and 26 were homozygous for Met
allele. Met-carriers were taken together in a single group. Geno-
type groups did not differ according to age, sex, profession and
handedness (see Table 1). All 643 subjects had complete genotype
information. The genotype distribution did not deviate from the
Hardy–Weinberg equilibrium (p=0.90).
As shown in Fig. 2, there were no significant genotype-
dependent differences in the z-transformed scores of the
left (Val/Val homozygous 0.029±0.97 (n=413), Met-carriers
0.001±0.98 (n=230); p=0.25, see Fig. 2), right (Val/Val homozy-
gous 0.048±0.96 (n=413), Met-carriers 0.043±1.05 (n=230);
p=0.12, see Fig. 2) and mean hippocampal volume (Val/Val
homozygous 0.041±0.97 (n=413), Met-carriers 0.023±1.01
(n=230); p=0.15, see Fig. 2). The difference between genotypes in
mean hippocampal volumes resulted in a non-significant g of 0.05
(p=0.58).Wedidnotobserveamaineffect of ageor sexaswell asno
Fig. 2. Barplot showing left, right and mean bilateral hippocampal volumes
[mm3]± standard deviation of our original data. Neither the left, right nor mean
bilateral hippocampus showed a significant difference between 230 Met-carriers
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interaction effect of sex and rs6265 genotype groups on hippocam-
pal volumes (see supplementarymethods and supplementary table
S3).
3.2. Description of studies and cohorts included in the
meta-analysis
A total of 4655 subjects in 32 datasets were selected for this
random-effects meta-analysis (Agartz et al., 2006; Bueller et al.,
2006; Cerasa et al., 2010; Chepenik et al., 2009; Cole et al., 2011;
Dutt et al., 2009; Frodl et al., 2007; Gatt et al., 2009; Gonul et al.,
2011; Gruber et al., 2012; Jessen et al., 2009; Joffe et al., 2009;
Koolschijn et al., 2010;Molendijk et al., 2012b;Montag et al., 2009;
Nemoto et al., 2006; Pezawas et al., 2004; Richter-Schmidinger
et al., 2011; Sanchez et al., 2011; Schofield et al., 2009; Smith et al.,
2012; Soliman et al., 2010; Stein et al., 2012; Stern et al., 2008;
Szeszko et al., 2005; Takahashi et al., 2008; Yang et al., 2012).
All 27 included studies were published between 2004 and 2012.
This structuralMRImeta-analysis comprises 1771Met-carriers and
2884 Val/Val homozygotes. For an overview of all included sam-
ples, see Table 2. Ethnicity was reported in 26 samples, of which
19 were performed on a Caucasian sample, 2 on a Japanese sam-
ple, 1 on a Chinese sample and 4 on a sample of mixed ethnicity.
The overall mean age of all datasets providing this informationwas
31.65±9.0. The Hardy–Weinberg equilibrium did not deviate in 28
datasets, whereas in 3 datasets this parameter could not be calcu-
lated due to insufficient data. Quality analysis showed that most of
the included studies were of high or moderate quality (44% high
and 48% moderate scores, supplementary table S1 and table S2).
3.3. Meta-analysis of one original and 31 previously published
samples
Meta-analysis of all datasets (k=32) showed evidence for sig-
nificant, albeit weak association between hippocampal volumes
and SNP rs6265 (g=0.09, se =0.04, 95% CI = [0.01–0.17], Z=2.08,
p=0.0376, see Fig. 3A and table S4), with indications of signifi-
cant between-study heterogeneity (I2 =38.24%, Q(df =31) =50.20,
p=0.02). The effect was in the direction of slightly smaller hip-
pocampal volumes for Met-carriers than for Val/Val homozygotes.
Visual inspection of the funnel plot indicated evidence for poten-
tial publication bias (Fig. 3B, table S4). This was quantitatively
confirmed by significant regression intercept in Egger’s regres-
sion test (p=0.0075). The trim and fill procedure suggested 8
missing studies on the left side of the funnel plot and a cor-
rected non-significant Hedge’s g of 0.02 (95% CI = [−0.07–0.11],
Fig. 3B). Meta-regression analysis did not reveal any effect for
age of participants (ˇ =−0.08, F(1,30) =0.18, p=0.67), gender ratio
(ˇ =0.13, F(1,30) =0.48, p=0.49), ethnicity of the subjects (ˇ =0.26,
F(1,25) =1.83, p=0.19), Val/Met ratio (ˇ =0.14, F(1,24) =0.48,
p=0.50), sample size (ˇ =−0.23, F(1,30) =1.71, p=0.20), quality
rating (ˇ =−0.32, F(1,24) =2.74, p=0.11), magnetic field strength
(ˇ =−0.22, F(1,28) =1.49, p=0.23), or hippocampal volumes nor-
malized to ICV (ˇ =−0.01, F(1,30) =0.002, p=0.96). However, the
analysis of the meta-regressions indicated a potential source for
bias related to measurement techniques (ˇ =0.43, F(1,29) =6.55,
p=0.02) (see Fig. 3C and table S4) andyear of publication (ˇ =−0.38,
F(1,30) =5.01, p=0.03) (see Fig. 3A, cumulative meta-analysis, and
table S4).
3.4. Effect of moderators
To further disentangle the moderating effect of the mea-
surement technique, samples were subsequently subdivided into
manually and automatically segmented volumes of the hip-
pocampi. One study using semi-automated analysis was excluded
fromfurther analysis (Sanchezet al., 2011), leaving13 sampleswith
manual tracing (n=829 subjects) and 18 samples using automated
segmentation (n=4426 subjects). The detected small effect size
estimate of manual tracing samples indicated significantly smaller
hippocampal volumes for Met-carriers compared to Val/Val sub-
jects (g=0.22, se =0.09, 95% CI = [0.05–0.39], Z=2.51, p=0.0121,
I2 =38.12%,Q(df = 12) =19.39, p=0.08, Trim and fill: 5missing stud-
ies on left side of the funnel plot and a corrected non-significant g
of 0.08, see Fig. 4A and table S4). The meta-analysis of the manual
tracing samples revealed significant publication bias (Egger’s test:
z=3.24, p=0.0012), significant between-study heterogeneity and
a significant moderator effect only for the sample size (ˇ =−0.72,
F(1,11) =12.07, p=0.01). Analysis of the relation between years of
publication and effect size revealed a significant decrease in the
effect sizes with increasing sample size over the years, but only
for manual tracing samples (see Fig. 5). In contrast, the overall
effect size of the samplesusing automaticmeasurement techniques
showed no significant genotype effect (g=0.04, se =0.05, 95%
CI = [−0.05–0.13], Z=0.89, p=0.3751, I2 =37.87%, Q(df = 17) =27.36,
p=0.05, see Fig. 4B and table S4).
4. Discussion
In this paper, we present a joint analysis of the relation
between the BDNF SNP rs6265 and the hippocampal volumes in
healthy young subjects. Specifically, we first exploredwhether hip-
pocampal volumes of 643 healthy individuals differed between
Val/Val homozygotes and Met-carriers. These data were further
incorporated into a meta-analysis of previously published studies
subsuming a total of 5298 healthy subjects.
Hippocampal volume is a heritable quantitative trait (estimates
vary between 40 and 69%). Hence, several studies have analyzed
the association between candidate genes, such as BDNF, and the
hippocampus (Goldman et al., 2008; Peper et al., 2007; Sullivan
et al., 2001). However, the studies investigating the association
betweenBDNFSNP rs6265andhippocampal volumes report incon-
sistentfindings. SomestudiesobserveBDNF-dependentdifferences
in hippocampal volumes (Bueller et al., 2006; Montag et al., 2009;
Pezawas et al., 2004; Schofield et al., 2009), whereas others do not
find an association (Agartz et al., 2006; Cerasa et al., 2010; Chepenik
et al., 2009; Cole et al., 2011; Dutt et al., 2009; Frodl et al., 2007;
Gatt et al., 2009; Gruber et al., 2012; Jessen et al., 2009; Joffe et al.,
2009; Koolschijn et al., 2010;Molendijk et al., 2012b; Nemoto et al.,
2006; Richter-Schmidinger et al., 2011; Sanchez et al., 2011; Smith
et al., 2012; Soliman et al., 2010; Stein et al., 2012; Stern et al., 2008;
Szeszko et al., 2005; Takahashi et al., 2008; Yang et al., 2012). The
results based on our own data as well as the meta-analysis across
studies applying automatic hippocampal segmentation do not sup-
port an association between rs6265 and hippocampal volumes.
Several studies report BDNF-dependent volume differences in
the hippocampus of patients with neuropsychiatric disorders such
as bipolar disorder and schizophrenia (Chepenik et al., 2009;
Szeszko et al., 2005) as well as between healthy controls and
patients of the same genotype (Chepenik et al., 2009; Gonul et al.,
2011; Koolschijn et al., 2010; Smith et al., 2012). Other studies
in patient populations found no association of the rs6265 poly-
morphism and hippocampal volumes (Agartz et al., 2006; Cerasa
et al., 2010; Cole et al., 2011; Dutt et al., 2009; Frodl et al., 2007;
Gruber et al., 2012; Jessen et al., 2009; Molendijk et al., 2012b;
Takahashi et al., 2008). Two recent meta-analyses did not find a
significant association of SNP rs6265 and hippocampal structure in
neuropsychiatric disorders, including schizophrenia, bipolar dis-
order, depressive and anxiety disorders (Kambeitz et al., 2012;
Molendijk et al., 2012a). However, themeta-analyseswere not con-
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Fig. 3. (A) Forest plots of random-effects meta-analysis assessing hippocampal volumes with structural MRI and the BDNF SNP rs6265. Positive effect sizes indicate larger
hippocampi in the Val allele subjects than with the Met allele subjects. The forest plot of a cumulative meta-analysis shows the change of the evidence over time. Dashed
lines indicate zero line. (B) Funnel plot with additional trim and fill procedure where white dots indicate the missing studies to correct for potential publication bias. (C)
Meta-regression analysis of the hippocampal measuring technique and the effect of the SNP rs6265, MT: manual tracing, AM: automatic measurement.
effects may have influenced the hippocampal volumes (Fusar-Poli
et al., 2013).
Inconsistent findings in studies of healthy subjects and psy-
chiatric patients raise the question if BDNF-dependent structural
hippocampal differences are specific for different developmental
stages. Until now, only few studies have addressed this issue by
investigating the relationship betweenBDNF andhippocampal vol-
umes in neonates, children and adolescents and also elderly. Two
studies have not observed BDNF-dependent differences in hip-
pocampal volumes in children and adolescents (age range 8–19)
(Mueller et al., 2013; Toro et al., 2009). In contrast, Knickmeyer
and colleagues find rs6265-dependent differences in hippocam-
pal volumes in neonates (Knickmeyer et al., 2013). However, in
order to investigate the influence of developmental stages on
BDNF-dependent effects, additional longitudinal studies will be
necessary. For instance, Knickmeyer and colleagueswill implement
a follow-up design, collecting data over several time points (at age
1, 2, 4 and 6 years of age) (Knickmeyer et al., 2013). Moreover,
several studies report hippocampal volume reductions in aging
(Driscoll et al., 2003; Erickson et al., 2010; Malykhin et al., 2008;
Raz et al., 2010). Erikson and colleagues investigated the relation-
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Fig. 4. Forest plots of BDNF SNP rs6265 of structural MRI studies assessing potential publication bias arising from the applied hippocampus analysis technique. (A) Manual
traced hippocampus; (B) Hippocampus volumes evaluated by automatic measurement; positive effect sizes indicate larger hippocampi in the Val allele subjects compared
to the Met-carriers. Dashed lines indicate zero line.
memory performance (Erickson et al., 2010). Age was associated
with reducedhippocampal volumes aswell as reducedBDNF serum
levels and poorer memory performance. In his review, Von Bohlen
und Halbach suggests a role of BDNF in age-dependent processes
in the hippocampus (Von Bohlen und Halbach, 2010). However,
studies investigating the association of rs6265 with hippocam-
pal volumes in also aged populations report inconsistent results
(Brooks et al., 2014; Karnik et al., 2010; Sanchez et al., 2011).
The importance of the hippocampus in learning and memory is
well established (Squire and Wixted, 2011) and it has been sug-
gested that BDNF plays a role in these processes (Baj et al., 2013;
Cunha et al., 2010). Even though we did not find BDNF-dependent
differences in hippocampal volumes, the absence of difference on
the anatomical level does not rule out that BDNF modulates other
processes in the hippocampus. Indeed, two studies included in this
meta-analysis provide support for BDNF-dependent differences in
Fig. 5. Scatter plot showing the relation between effect size and year of publication
for the association of the hippocampal volume and BDNF SNP rs6265. The size of the
shapes indicates the sample size of each study. Squares represent the studies that
traced the hippocampus manually; circles represent the studies that measured the
hippocampus automatically. Dashed line indicates zero line.
hippocampal activation during memory paradigms in the absence
of structural differences (Cerasa et al., 2010; Molendijk et al.,
2012b), which is further supported by additional studies analyzing
functional MRI data (Dennis et al., 2011; Egan et al., 2003; Hariri
et al., 2003; Hashimoto et al., 2008). However, the meta-analysis
by Kambeitz and colleagues did not find an association between
rs6265 and hippocampus-mediated memory activation, which
might be explained by the large variety of paradigms combining
working and episodic memory processes (Kambeitz et al., 2012).
Moreover, meta-analyses assessing an association between rs6265
and declarative memory performance revealed contradictory
results (Kambeitz et al., 2012; Mandelman and Grigorenko, 2012).
In our meta-analysis we observed an effect of the applied mea-
suring technique (manually traced vs. automatically measured
hippocampal volumes) after we investigated the effect of sev-
eral moderators due to significant between-study heterogeneity
and publication bias. First, the overall meta-analysis showed a
weakly (g=0.09) significant association between hippocampal vol-
umes and SNP rs6265. In particular, Val/Val homozygotes had
significantly larger hippocampal volumes than Met-carriers. The
direction of the effect is in accordance with recent meta-analyses
of healthy subjects (Hajek et al., 2012; Kambeitz et al., 2012;
Molendijk et al., 2012a), but the effect size in this studywas consid-
erably smaller. To further disentangle the dissociable effect of these
two measurement approaches, subsequent analyses were con-
ductedafter separating the samplesby thehippocampusmeasuring
technique. We found that Met-carriers had smaller hippocampal
volumes thanVal/Val homozygotes (g=0.22)when thehippocampi
were manually segmented. In contrast, we did not find a signifi-
cant genotype effect with automatic segmentation (g=0.04). This
latter result is consistent with the findings of our original sample
in 643 healthy subjects, where we used the automatic segmenta-
tion technique from FreeSurfer and also with the results of a recent
GWAS analysis in 5776 healthy subjects (Stein et al., 2012). Even
though manual segmentation is generally considered as the gold
standard due to the precise delineation of anatomical structures,
the increasing sample size of imaging studies renders the pro-
cess of manual segmentation less practicable, as it is both costly
and time consuming. Several studies compared manual and dif-
ferent automatic segmentation methods and report comparable
accuracy, sensitivity and reproducibility (Bergouignan et al., 2009;
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Specifically, automated segmentation of the hippocampus using
FreeSurfer shows higher correlations with manual segmentation
compared to FSL/First (Doring et al., 2011; Morey et al., 2009).
Nonetheless, it has been shown that, compared to manual seg-
mentation, FreeSurfer and FSL overestimate hippocampal volumes
(Doring et al., 2011; Morey et al., 2009) while they are under-
estimated by SACHA (Bergouignan et al., 2009). However, our
meta-analysis across studies using only manual tracing samples
revealed a publication bias, between-study heterogeneity and a
moderator effect for the sample size. These effects were further
studied in detail to investigate the relation between sample size
and publication year. We showed that effect sizes shrink as a func-
tion of publication year and sample size. In contrast to the findings
of previous meta-analyses (Kambeitz et al., 2012; Molendijk et al.,
2012a), this decrease in effect size could not be attributed to pub-
lication year alone, but was also linked to an increase in sample
size.
Several limitations of our analyses need to be considered. In our
meta-analysis, we could not address laterality differences or differ-
ences in specific hippocampal sub-regions as many of the included
studies only report total hippocampal volumes. Furthermore, we
explicitly focused on the impact of the rs6265 polymorphism on
hippocampal volumes in healthy subjects, without considering the
effect of other SNPs, gene-gene interactions (Honea et al., 2009)
or gene-environment interactions (Gatt et al., 2009; Gerritsen
et al., 2012). This is of particular relevance, as the impact of the
BDNF SNP rs6265 on hippocampal volume could be modified by
other SNPs that have already been shown to impact the volume
of the hippocampus, such as the Val159Met polymorphism of
catecholamine-O-methyltransferase (COMT) (Cerasa et al., 2008;
Dutt et al., 2009; Ehrlich et al., 2010; Honea et al., 2009; Taylor
et al., 2007), an SNP of ZNF804a (Donohoe et al., 2011; Wei et al.,
2012) or the intergenic variant rs7294919 (Stein et al., 2012).
Finally, we did not observe a main effect of sex and age on hip-
pocampal volumes, nor did we observe an interaction effect of
sex and genotype on hippocampal volumes. Other studies found
sex- (Cahill, 2006; Goldstein et al., 2001; Liu et al., 2010; Ruigrok
et al., 2013), and age-dependent differences in hippocampal vol-
umes (Driscoll et al., 2003; Malykhin et al., 2008; Raz et al., 2010).
Since the association of rs6265 and age-dependent hippocampal
changes revealed controversial results (Brooks et al., 2014; Karnik
et al., 2010; Sanchez et al., 2011) and the role of sex in this asso-
ciation is not well understood, it would be interesting if future
studies would address these questions. Potential reasons for the
absence of such effects in our original study are the applied cor-
rection for intracranial volume and the limited age-range of our
sample.
In summary, the present study does not support the association
between SNP rs6265 and hippocampal volumes in healthy individ-
uals. Theweakeffect observed in themeta-analysis ismainlydriven
by studies with small sample sizes applying manual segmentation
of hippocampi. Our findings confirm the results of previous results
based on a large sample size. Moreover, our findings demonstrate
an effect of measuring techniques, publication year and sample
size.
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Sample quality control with Bayesian clustering algorithm 
Within each center, the Bayesian Clustering Algorithm31 was applied on genome-
wide summary statistics to identify and exclude atypical samples. Considering a 
combination of two summary statistics, the algorithm infers each sample's posterior 
probability to belong to the outliers class. A first outlier assessment was based on 
genome-wide call rate and heterozygosis rates, for which extreme values may be 
indicative of genotyping bias. A second assessment, aiming at identifying subjects 
with unusual ancestry according to the majority of the samples, was performed by 
projection of the samples genotypic data on the two first components inferred from a 
PCA applied on Hapmap African, European and Asian populations. Samples were 
also checked for consistency between genotypic inferred and self-reported gender. 
 
Investigation of main effect of age or sex and interaction effect of sex and rs6265 
genotype groups on hippocampal volumes 
Additionally, we specified univariate ANOVA for each variable of interest using sum 
of square type III. Hippocampal volumes, as the (quantitative) dependent variable, 
were corrected separately for ICV, differences due to software and gradient updates 
and either sex or age by using the z-transformed residuals of a linear regression. 
Independent variables were age as quantitative variable, sex and rs6265 genotype 







Table S1 Categories scored in the quality assessment 
max 22. high (80-100%) >18, moderate-high (60-79%): 14-17, moderate (40-59%): 



















Category 0 1 2 




drug or missing 
could have  none 
2. Sample size < 20 20 - 29 30 + 
3. Clear inclusion criteria for participants  not reported partly reported reported 
4. Reported allele distribution not reported . reported 
5. Ethnicity assessed not reported . reported 
6. If mixed ethnicity: Discussing problems not included included . 
7. IQ/educational level available not reported . reported 
8. Inter-and intrarater reliability not reported . reported 
9. Hardy-Weinberg equilibrium reported not reported matched sample reported 
10. Sample in Hardy-Weinberg equilibrium not reported/ not 
enough data to 
calculate 
matched sample reported 
11. Sufficient descriptive data (age, gender, 
genotyping method, magnetic field strength 
of scanner) 





Table S2 Quality assessment and rating of the published studies 
Author, Year 1 2 3 4 5 6 7 8 9 10 11 Sum of the score & 
category 
Agartz et al., 2006 0 2 2 2 2 2 0 2 0 2 2 16 moderate-high 
Bueller et al., 2006 1 2 2 2 2 0 2 0 2 2 2 17 moderate-high 
Cerasa et al., 2010 0 2 2 2 2 2 2 0 2 2 2 18 high 
Chepenik et al., 2009 1 0 1 2 2 2 0 2 0 2 2 14 moderate-high 
Cole et al., 2011 2 2 2 2 0 0 2 2 2 2 2 18 high 
Dutt et al., 2009 2 2 2 0 2 2 0 0 2 2 2 16 moderate-high 
Frodl et al., 2007 0 2 2 2 0 0 0 2 2 2 2 14 moderate-high 
Gatt et al., 2009 1 2 0 0 2 2 2 2 2 2 2 17 moderate-high 
Gonul et al., 2011 2 2 1 0 0 0 0 2 2 2 2 13 moderate 
Gruber et al., 2012 0 2 2 2 2 2 2 2 2 2 1 19 high 
Jessen et al., 2009 0 2 2 0 0 0 0 2 0 0 2 8 moderate-low 
Joffe et al., 2009 1 2 2 2 2 2 0 2 2 2 1 18 high 
Koolschijn et al., 2010 0 2 1 2 2 2 0 2 2 2 2 17 moderate-high 
Millan Sanchez et al., 2011 2 2 1 0 2 2 2 2 0 0 1 14 moderate-high 
Molendijk et al., 2012 2 2 1 2 0 0 2 2 2 2 1 16 moderate-high 
Montag et al., 2009 2 2 2 2 2 2 0 2 2 2 2 20 high 
Nemoto et al., 2006 1 2 2 2 2 2 2 2 2 2 2 21 high 
Pezawas et al., 2004 0 2 2 0 2 2 2 2 0 0 2 14 moderate-high 
Richter-Schmidinger et al., 
2011 0 2 2 2 2 2 2 2 0 2 2 18 high 
Schofield et al., 2009 0 2 2 2 0 0 2 2 2 2 2 16 moderate-high 
Smith et al., 2012 2 2 2 0 0 0 0 2 2 2 2 14 moderate-high 
Soliman et al., 2010 0 2 2 2 2 2 0 0 0 2 2 14 moderate-high 
Stern et al., 2008 2 2 2 2 2 2 2 0 0 2 2 18 high 
Szeszko et al., 2005 1 1 2 2 2 2 2 2 2 2 2 20 high 
Takahashi et al., 2008 2 1 2 2 2 2 0 2 2 2 2 19 high 
Yang et al., 2012 2 2 2 2 2 2 2 0 2 2 2 20 high 
















Table S3 Main effect of age and sex as well as interaction effect of sex and rs6265 
genotype on hippocampal volumes 
Variables left hippocampus volume 
     F (df)                      p-values 
right hippocampus volume 
         F (df)                     p-values 
bilateral hippocampal volumes 
      F (df)                           p-values 
age 1.32 (1,640) 0.200 1.29 (1,640) 0.257 1.64 (1,640) 0.201 
sex 0.87 (1,640) 0.352 0.01 (1,640) 0.943 0.209 (1,640) 0.648 
sex x rs6265 






































Table S4 Overview of the results form the performed meta-analyses 
 All samples  




(k = 13, n = 829) 
Automatically 
segmented 
hippocampi (k = 
18, n = 4426) 
Hedge's g  0.09 0.22 0.04 
Standard error  0.04 0.09 0.05 
Lower confidence interval  0.01 0.05 -0.05 
Upper confidence interval  0.17 0.39 0.13 
Z-value  2.08 2.51 0.89 
p-value of Z  0.0376* 0.0121* 0.3751 
Heterogeneity I2  38.24 38.12 37.87 
Heterogeneity Q (df)  50.20 (31) 19.39 (12) 27.36 (17) 
p-value of Q  0.02* 0.08 0.05 














Publication year b-value -0.38 -0.42 -0.18 
F-value (df) 5.01 (30) 2.32 (11) 0.52 (16) 
p-value 0.03* 0.16 0.48 
Age of probands b-value -0.08 -0.33 0.01 
F-value (df) 0.18 (30) 1.37 (11) 0.002 (16) 
p-value 0.67 0.27 0.97 
Gender ratio b-value 0.13 0.26 0.07 
F-value (df) 0.48 (30) 0.80 (11) 0.08 (16) 
p-value 0.49 0.39 0.78 
Ethnicity b-value 0.26 0.53 0.25 
F-value (df) 1.83 (25) 2.74 (7) 1.03 (16) 
p-value 0.19 0.14 0.33 
Val/Met ratio b-value 0.14 0.29 -0.02 
F-value (df) 0.48 (24) 0.80 (9) 0.01 (13) 
p-value 0.5 0.4 0.94 
Sample size b-value -0.23 -0.72 -0.1 
F-value (df) 1.71 (30) 12.07 (11) 0.15 (16) 
p-value 0.2 0.01* 0.7 
Quality rating b-value -0.32 -0.35 -0.17 
F-value (df) 2.74 (24) 1.51 (11) 0.32 (11) 
p-value 0.11 0.25 0.58  
Hippocampal volume 
normalized to ICV 
b-value -0.01 0.22 0.03 
F-value (df) 0.002 (30) 0.54 (11) 0.01 (16) 
p-value 0.96 0.48 0.91 
Magnetic field strength b-value -0.22 -0.07 -0.1 
F-value (df) 1.49 (28) 0.06 (11) 0.14 (15) 
p-value 0.23 0.82 0.71 
Hippocampal measuring 
technique 
b-value 0.43 - - 
F-value (df) 6.55 (29) - - 
p-value 0.02* - - 
Abbreviations: k, number of included studies; n, number of included individuals; *, 
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a  b  s  t  r  a  c  t
Background:  Brain-derived  neurotrophic  factor  (BDNF)  is  a neurotrophin  involved  in  neurogenesis  and
synaptic  plasticity  in  the  central nervous  system,  especially  in  the  hippocampus,  and has  been  implicated
in  the  pathophysiology  of  several  neuropsychiatric  disorders.  Its  Val66Met  polymorphism  (refSNP  Cluster
Report:  rs6265)  is a  functionally  relevant  single  nucleotide polymorphism  affecting  the  secretion  of BDNF
and  is  implicated  in  differences  in  hippocampal  volumes.
Methods: This  is a systematic  meta-analytical  review  of  findings  from  imaging  genetic  studies  on  the
impact  of the rs6265  SNP  on  hippocampal  volumes  in neuropsychiatric  patients  with  major  depressive
disorder,  anxiety,  bipolar  disorder  or schizophrenia.
Results: The  overall  sample  size  of 18 independent  clinical  cohorts  comprised  1695  patients.  Our  results
indicated  no  significant  association  of  left (Hedge’s  g = 0.08,  p = 0.12), right  (g  = 0.07,  p  =  0.22) or bilateral
(g  =  0.07,  p = 0.16) hippocampal  volumes  with  BDNF  rs6265  in neuropsychiatric  patients.  There  was  no
evidence  for  a publication  bias  or any  demographic,  clinical,  or methodological  moderating  effects.
Both  Val/Val  homozygotes  (g =  0.32,  p =  0.004)  and  Met-carriers  (g = 0.20,  p  = 0.004)  from  the patient
sample  had  significantly  smaller hippocampal  volumes  than  the healthy  control  sample with the same
allele.  The magnitude  of these effects  did not  differ  between the  two  genotypes.
Conclusion: This  meta-analysis  suggests  that  there  is  no association  between  this  BDNF  polymorphism
and  hippocampal  volumes.  For each  BDNF genotype,  the  hippocampal  volumes  were  significantly  lower
in  neuropsychiatric  patients  than  in  healthy controls.
©  2015  The Authors.  Published  by Elsevier  Ltd. This is an open  access  article under  the CC  BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Hippocampal atrophy is a common characteristic of neuropsy-
chiatric disorders, such as major depressive disorder, bipolar
disorder, anxiety disorders and schizophrenia (Buehlmann et al.,
2010; Fusar-Poli et al., 2007; Geuze et al., 2005; Kempton et al.,
2011; Shepherd et al., 2012). The hippocampus has been intensely
studied, as it is involved in learning and memory-dependent pro-
cesses (Kandel, 2001; McDonald and Hong, 2013; Preston and
Eichenbaum, 2013) and due to the occurrence of cognitive impair-
ment in neuropsychiatric disorders (Bora et al., 2010; Bourne
et al., 2013; Fusar-Poli et al., 2012; Schaefer et al., 2013; Snyder,
2013).
Brain-derived neurotrophic factor (BDNF) is a widely investi-
gated marker in neuropsychiatric disorders and may  be important
in the pathophysiology of depression (Buchmann et al., 2013;
Karege et al., 2002; Lang and Borgwardt, 2013; Shimizu et al., 2003),
bipolar disorder (Cunha et al., 2006) and schizophrenia (Niitsu et al.,
2014; Numata et al., 2006). BDNF protein is involved in neuro-
genesis and neuroplasticity in the brain. Proper BDNF signalling
requires both pro-BDNF and mature BDNF. BDNF concentrations
can be measured in serum, plasma or whole blood. These concen-
trations are highly correlated with those in cerebrospinal fluid,
as BDNF crosses the blood-brain barrier (Pan et al., 1998; Pillai
et al., 2010). Several meta-analyses have shown that there may
be a correlation between low BDNF levels and the emergence of
depression (Fernandes et al., 2014; Molendijk et al., 2014), bipolar
disorder (Fernandes et al., 2014, 2011; Lin, 2009) and schizophrenia
(Fernandes et al., 2014; Green et al., 2011). The critical role of BDNF
in neuropsychiatric diseases is further reflected by the fact that its
level can be increased by neuropsychiatric medications, such as
antidepressants, mood stabilisers and antipsychotics (Choi et al.,
2006; Dmitrzak-Weglarz et al., 2008; El-Hage et al., 2014; Grande
et al., 2014; Hong et al., 2003; Perkovic et al., 2014; Ricken et al.,
2013; Rybakowski et al., 2005; Tsai et al., 2003; Xu et al., 2010; Zai
et al., 2012; Zou et al., 2010).
The single nucleotide polymorphism (SNP) Val66Met, also
known as G189A or rs6265, represents substitution of a valine (Val)
by a methionine (Met) at codon 66. This substitution in the pro-
region of BDNF modifies sorting of the protein and its availability
in the synaptic cleft. Met/Met transgenic mice exhibit less activity-
dependent BDNF, with smaller hippocampal volumes, decreased
complexity of the dendritic arbor of hippocampal neurons (Chen
et al., 2004, 2006; Ninan et al., 2010; Egan et al., 2003) and
impaired synaptic plasticity, as indicated by a decrease in NMDA
receptor-dependent long-term depression and long-term poten-
tiation (Ninan et al., 2010). Several studies have demonstrated
an association between rs6265 polymorphism and neuropsychi-
atric disorders (e.g. Chen et al., 2008; Gratacòs et al., 2007; Lohoff
et al., 2005; Sklar et al., 2002), although just as many have found
no effect (e.g. Frustaci et al., 2008; González-Castro et al., 2014;
Kanazawa et al., 2007; Verhagen et al., 2008). However, these asso-
ciation studies may  indicate that the Met  allele is protective for
bipolar disorder, but is a risk allele for depression and schizophre-
nia. More specifically, several studies have investigated the effect of
this BDNF polymorphism on brain volumes of patients with depres-
sion, bipolar disorder or schizophrenia (Aas et al., 2013; Agartz
et al., 2006; Chepenik et al., 2009; Cole et al., 2011; Dutt et al.,
2009; Frodl et al., 2007; Gonul et al., 2011; Gruber et al., 2012; Ho
et  al., 2006, 2007; Jessen et al., 2009; Kanellopoulos et al., 2011;
Koolschijn et al., 2010; Molendijk et al., 2014; Smith et al., 2012;
Stein et al., 2012; Szeszko et al., 2005; Takahashi et al., 2008). Many
of these studies have focussed on the hippocampus, where BDNF
has been shown to play a role in normal learning and memory
(Baj et al., 2013; Cunha et al., 2010) and learning- and memory-
dependent deficits in neuropsychiatric disorders (Baig et al., 2010;
Egan et al., 2003; Lau et al., 2010; Molendijk et al., 2012b; Ninan,
2014) may  be associated with declines in hippocampal volume.
Two previous meta-analyses have investigated the association of
BDNF rs6265 and hippocampal volumes using MRI  techniques in a
neuropsychiatric patient sample (Kambeitz et al., 2012; Molendijk
et al., 2012a). Both studies reported smaller hippocampal volumes
for Met-carriers than for Val/Val homozygotes, but the differences
were non-significant. This is in line with our recently published
meta-analysis of healthy individuals that did not indicate a sig-
nificant association between the SNP and hippocampal volumes
(Harrisberger et al., 2014). In contrast, studies of the effect of the
BDNF val66met in major depressive disorder and psychosis found
that the status of Met-carrier and exposure to childhood trauma
have an interactive effect on hippocampus volume (Aas et al., 2013;
Carballedo et al., 2013). The available meta-analyses addressing
hippocampal volumes in neuropsychiatric patients genotyped for
SNP rs6265 included relatively small samples and yielded incon-
clusive results (Kambeitz et al., 2012; Molendijk et al., 2012a).
To overcome this lack of knowledge and to reconcile inconsis-
tencies across individual studies, we  present here the first robust
quantitative meta-analysis of BDNF rs6265 effects on hippocam-
pal volumes in different neuropsychiatric disorders. In the present
meta-analysis of a total of 1695 individuals, we  sought to explore a
putative association between hippocampal volumes and the BDNF
polymorphism in neuropsychiatric disorders, such as major depres-
sive disorder, bipolar disorder, anxiety disorders or schizophrenia.
Furthermore, we  investigated whether the Met  allele can be des-
ignated as a “risk” or as a “protective” allele in relation to the
hippocampus volume. We  therefore examined for the first time the
risk that patients had smaller hippocampal volumes than healthy
controls, both for Val/Val homozygote individuals and for Met car-
riers.
2. Materials and methods
We  followed the “Preferred Reporting Items for Systematic
Reviews and Meta-Analyses” (PRISMA) guidelines (Moher et al.,
2010).
2.1. Literature search strategy and selection of studies
The electronic databases PubMed and Embase were searched,
with consideration of all publications with the following search
terms: “BDNF Val66Met” AND “MRI” and “rs6265” AND “MRI” pub-
lished until the end of May  2014. In addition, the reference lists of
the included articles were reviewed. This resulted in 79 publica-
tions, from which the abstracts were screened (more information
is presented in Fig. 1). In this meta-analysis, we included stud-
ies addressing the relation between hippocampal volumes and
the SNP rs6265 in neuropsychiatric patients using the follow-
ing inclusion criteria: (a) published in a peer-reviewed journal,
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Fig. 1. Flow chart of the search strategy and studies included in the meta-analysis.
magnetic resonance imaging (sMRI), and (c) showing hippocampal
data. A total of 15 publications met  these criteria and, in addition,
data from three independent cohorts were obtained. Altogether
a total of 18 datasets were included in this meta-analysis. Cri-
teria for exclusion were as follows: non-neuropsychiatric brain
disorder (multiple sclerosis; Dinacci et al., 2011; Liguori et al.,
2009; Ramasamy et al., 2011; Weinstock-Guttman et al., 2007;
Zivadinov et al., 2007), Alzheimer’s disease (Honea et al., 2013; Lim
et al., 2014; Voineskos et al., 2011), reversible cerebral vasocon-
striction syndrome (Chen et al., 2011), alcohol-dependence (Mon
et al., 2013), premenstrual dysphoric disorder (Comasco et al.,
2014), obesity (Marqués-Iturria et al., 2014)), no clearly defined
patient group, overlapping datasets, and only left or right hip-
pocampal volumes reported. The authors were contacted when
essential information was missing for the calculation of effect
sizes.
2.2. Data extraction
We  extracted the following variables: First author, publication
year, number of independent samples per study. For each inde-
pendent sample, we extracted sample size of genotype subgroups,
ethnicity, gender, mean age, Hardy–Weinberg equilibrium (HWE;
calculated, when not reported), genotyping method, structural MRI
measurement technique, direction of effect, field strength of MR
scanner, disorder itself, duration of disorder, age of onset of dis-
order and medication (antipsychotics, antidepressants), whether
the hippocampal volumes were normalised to intracranial volume
(ICV) or not and finally, mean hippocampal volumes and standard
deviation per genotype or corresponding t-statistic, F-statistic and
p-values. One single effect size per sample was included in this
meta-analysis, in order to sustain statistical independence.
2.3. Quality assessment
The  Newcastle-Ottawa Scale (NOS) (Wells et al., 2014) was
adapted to assess the quality of each study as recommended by
the Higgins and Green (2011) (“Cochrane Handbook for Systematic
Reviews of Interventions”). 0 or 1 point was  awarded for each of the
eight criteria, giving a total score of high (above 80% of the maxi-
mal sum of points), moderately high (60–79%), moderate (40–59%),
moderately low (20–39%), or low (below 19%). The mean quality
was moderately high at 76% (for more details see Supplementary
Table 1).
2.4.  Meta-analytic procedure
Quantitative  meta-analysis was performed using R 3.0.2 sta-
tistical software (R Core Team, 2012). The extracted data were
converted to Hedge’s g effect sizes, which provides an unbiased
standardised mean difference and – in contrast to Cohen’s d – incor-
porates a correction for small sample sizes (Lipsey and Wilson,
2000). Hedge’s g was calculated from mean hippocampal vol-
umes, standard deviations and sample sizes; where these data were
not available, the t-statistic, F-statistic or p-values together with
the corresponding sample sizes were used. Random effects model
were employed with the DerSimonian–Laird estimator, using the
metafor package 1.9.2 in R (DerSimonian and Laird, 1986; Wolfgang
Viechtbauer, 2010). The random effects model shows more flexibil-
ity with respect to variable effect size in different studies and study
populations (Cooper et al., 2009), as it incorporates the between-
study variance !2. With high between-study heterogeneity, the
random effects model is the model of choice, rather than the fixed-
effects model (Ioannidis et al., 2007). Cochran’s Q test was used
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and the magnitude of heterogeneity was assessed by I2 (I2 > 50%:
high) (Higgins and Thompson, 2002). We  investigated potential
publication bias by funnel plot asymmetry and Egger’s regression
test (Egger et al., 1997). In the presence of a bias, the “trim-and-fill”
method was performed (Duval and Tweedie, 2000). Power analy-
sis was performed using G*Power (Faul et al., 2007). For sensitivity
analysis, the potential influence of each individual study was  exam-
ined by excluding each study in turn (Viechtbauer and Cheung,
2010). Moreover, meta-regression analyses were carried out to
assess the impact of possible moderating factors such as publica-
tion year, age of participants, gender ratio, ethnicity, Val/Met ratio,
sample size, quality rating, magnetic field strength, type of disorder
(major depressive disorder, bipolar disorder, anxiety disorders and
schizophrenia) and applied hippocampal measuring techniques. All
but two studies used a dominant allele approach (Agartz et al.,
2006; Gruber et al., 2012). Nevertheless, these were treated equiv-
alently in this analysis. Data from healthy individuals is available
in Harrisberger et al. (2014). Finally, effect sizes were compared to
assess whether Val/Val homozygotes or Met-carriers with a neu-
ropsychiatric disorder might have a greater risk of hippocampal
loss.
3. Results
3.1. Description of studies
All  included studies were published between 2005 and 2013.
A total of 1695 subjects from 18 independent datasets were
selected for this random effects meta-analysis (mean age ± SD:
43.13 ± 11.13 years, 56% females) (Aas et al., 2013; Agartz et al.,
2006; Chepenik et al., 2009; Cole et al., 2011; Dutt et al., 2009;
Frodl et al., 2007; Gonul et al., 2011; Gruber et al., 2012; Jessen
et al., 2009; Kanellopoulos et al., 2011; Koolschijn et al., 2010;
Molendijk et al., 2012b; Smith et al., 2012; Szeszko et al., 2005;
Takahashi et al., 2008). The meta-analysis of structural MRI  hip-
pocampal volumes comprised 661 Met-carriers and 1034 Val/Val
homozygotes. Ethnicity was reported in 14 samples, of which 11
were of Caucasian origin, one a Japanese sample and two of mixed
ethnicity. The Hardy–Weinberg equilibrium did not deviate in 17
datasets, whereas this parameter could not be calculated from
one dataset, due to insufficient data. The assessment of the BDNF
rs6265 genotype frequency showed similar results for all disorders
(Supplementary Fig. 1A). A comparison of the mean hippocampal
volumes in Val/Val homozygotes and Met-carriers for each disor-
der separately resulted in non-significant volumetric alterations
between the genotypes of each disorder (Supplementary Fig. 1B).
Details of the included studies are presented in Table 1. Quality
analysis showed that most of the included studies were rated as
being of high or moderately high quality (22% and 50%, respectively,
Supplementary Table 1).
3.2. Meta-analysis of neuropsychiatric patients
The random effects meta-analysis of all datasets (k = 18,
n = 1695) showed no evidence for a significant association
between hippocampal volumes and the BDNF SNP rs6265 (g = 0.11,
95%CI = [−0.02–0.25], p = 0.11, see Supplementary Fig. 2A and
Table 2). The visual inspection of the funnel plot and the Egger’s
regression test (p = 0.03) revealed a potential publication bias. In
order to account for this bias, the trim-and-fill procedure sug-
gested one missing study on the left side of the funnel plot, leading
to a smaller effect size (g = 0.09, 95%CI = [−0.06–0.25], p = 0.22),
(Table 2). Evidence of moderate between-study heterogeneity was
detected (I2 = 38.29%, Q(df = 17) = 27.55, p = 0.05), while a meta-
regression analyses indicated that this can probably be explained,
in  part, by the year of publication (  ˇ = −0.53, F(1,16) = 6.34, p = 0.02,
Fig. 2C, Table 2). The other tested confounders, age of participants,
gender ratio, ethnicity, Val/Met ratio, sample size, quality rating,
magnetic field strength, type of disorder (major depressive dis-
order, bipolar disorder, anxiety disorders or schizophrenia) and
applied hippocampal measuring techniques did not significantly
influence the meta-analytic result (Table 2). Power analysis sug-
gested that 1665 Val/Val homozygote and 1065 Met-carriers (2730
patients in total) would be necessary to achieve a power of 80%
at !-level of 0.05 (two-sided). Sensitivity analysis indicated that
two studies (Chepenik et al., 2009; Szeszko et al., 2005) with stan-
dardised residuals larger than ± 1.96 might be potential outliers
(Supplementary Fig. 3). Removal of these two studies might reduce
the amount of heterogeneity and increase the precision of the effect
size.
After excluding these two studies (k = 16, n = 1656), the mixed-
effect model showed an even smaller and non-significant effect
size (g = 0.07, 95%CI = [−0.03–0.22], p = 0.16, see Fig. 2A and
Table 2), but with a non-significant Egger’s regression test (p = 0.98)
and no significant between-study heterogeneity (I2 = 0.75%,
Q(df = 15) = 15.11, p = 0.44). The investigation of the lateral dif-
ferences revealed the same magnitude of effect as in the latter
meta-analysis, using either left (g = 0.09, 95%CI = [−0.02–0.19],
p = 0.12, k = 14, n = 1541, see Supplementary Fig. 2B and Table 2) or
right hippocampal volumes (g = 0.08, 95%CI = [−0.05–0.20], p = 0.22,
k = 14, n = 1541, see Supplementary Fig. 2C and Table 2). Data from
two studies were not available and could not be included (Agartz
et al., 2006; Gruber et al., 2012).
3.3. Meta-analysis of patients versus healthy controls with the
same  allele
Furthermore, we  investigated the difference in magnitude
between patients and healthy controls of the same genotype,
using the recessive model of the BDNF Val allele. For this anal-
ysis, one study was  excluded from further analysis due to the
lack of a healthy control sample (Aas et al., 2013) and two  stud-
ies could not be further included because of missing data (Agartz
et al., 2006; Gruber et al., 2012). The meta-analysis of Val/Val
homozygous individuals (k = 13, n = 2265) revealed that Val/Val
homozygous neuropsychiatric patients had smaller hippocam-
pal volumes than Val/Val homozygous healthy controls (g = 0.32,
95%CI = [0.11–0.54], p = 0.004, see Fig. 3A and Table 2). The meta-
analysis of Met-carriers (k = 13, n = 1255) indicated that Met-carrier
neuropsychiatric patients had smaller hippocampal volumes than
did Met-carrier healthy controls (g = 0.20, 95%CI = [0.06–0.33],
p = 0.004, see Fig. 3B and Table 2). As expected, the effect was  in
the direction of smaller hippocampal volumes for patients than for
healthy controls for both alleles. However, the effect sizes were
not significantly different for these two comparisons (F(1,24) = 0.36,
p = 0.55)). Visual inspection of the funnel plot as well as the
Egger’s regression test (p = 0.10, p = 0.13) indicated no potential
bias. No moderator was detected as a potential source of hetero-
geneity, although the between-study heterogeneity for the Val/Val
meta-analysis was  high and significant (p < 0.0001) (Table 2). Sep-
arate inspection of left and right hippocampal volumes for Val/Val
homozygotes and Met-carriers revealed comparable effect-sizes
to the combined meta-analysis (see Supplementary Fig. 2D–G and
Table 2).
4.  Discussion
This meta-analysis addressed the relation between hippocam-
pal volumes and the BDNF rs6265 genotype in a neuropsychiatric
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Table  2



















All patient data (k = 18,
n  = 1695)
0.11 0.07 −0.02 0.25 1.61 0.11 38.29 27.55 (17) 0.05
MA  without 2 studies
(k  = 16, n = 1656)
0.07 0.05 −0.03 0.18 1.42 0.16 0.75 15.11 (15) 0.44
MDD  only (k = 8,
n  = 903)
0.08 0.07 −0.05 0.22 1.21 0.23 0.00 5.84 (7) 0.56
L  Hippocampus (k = 14,
n  = 1541)
0.09 0.06 −0.02 0.19 1.54 0.12 3.53 13.48 (13) 0.41
R  Hippocampus (k = 14,
n  = 1541)
0.08 0.06 −0.05 0.20 1.22 0.22 22.97 16.88 (13) 0.21
Patient  vs. HC Val
(k  = 13, n = 2265)
0.32 0.11 0.11 0.54 2.92 0.004* 77.37 53.03 (12) <0.0001*
Patient vs. HC Val L
(k  = 13, n = 2265)
0.31 0.11 0.10 0.52 2.92 0.004* 75.31 4860 (12) <0.0001*
Patient vs. HC Val R
(k  = 13, n = 2265)
0.29 0.12 0.06 0.51 2.47 0.01* 79.60 58.82 (12) <0.0001*
Patient vs. HC Met
(k  = 13, n = 1255)
0.20 0.07 0.06 0.33 2.89 0.004* 7.58 12.98 (12) 0.37
Patient  vs. HC Met L
(k  = 13, n = 1255)
0.22 0.07 0.08 0.35 3.10 0.002* 11.44 13.55 (12) 0.33
Patient  vs. HC Met R
(k  = 13, n = 1255)
0.18 0.08 0.02 0.34 2.22 0.03* 30.52 17.27 (12) 0.14





















All patient data (k = 18,
n  = 1695)
0.03 1 0.02* 0.51 0.39 0.53 0.28 0.85 0.51 0.45
MA  without 2 studies
(k  = 16, n = 1656)
0.98  0 0.40 0.69 0.80 0.51 0.98 0.80 0.27 0.84
MDD  only (k = 8,
n  = 903)
0.75 0 0.37 0.94 na 0.27 0.84 0.41 0.54 0.98
L  Hippocampus (k = 14,
n  = 1541)
0.85 1 0.26 0.74 0.71 0.79 0.83 0.39 0.15 0.87
R  Hippocampus (k = 14,
n  = 1541)
0.60 1 0.79 0.47 0.72 0.45 0.74 0.80 0.22 0.97
Patient  vs. HC Val
(k  = 13, n = 2265)
0.10  0 0.43 na na 0.26 0.11 0.93 0.36 0.30
Patient  vs. HC Val L
(k  = 13, n = 2265)
0.002  0 0.27 na na 0.49 0.02* 0.43 0.76 0.03
Patient  vs. HC Val R
(k  = 13, n = 2265)
0.96  0 0.45 na na 0.48 0.50 0.83 0.56 0.56
Patient  vs. HC Met
(k  = 13, n = 1255)
0.13  2 0.44 na na 0.25 0.36 0.21 0.57 0.05
Patient  vs. HC Met L
(k  = 13, n = 1255)
0.07  2 0.20 na na 0.42 0.24 0.47 0.39 0.04*
Patient vs. HC Met R
(k  = 13, n = 1255)
0.47  0 0.88 na na 0.07 0.57 0.16 0.89 0.15
Abbreviation: MDD: major depressive disorder; Met: methionine; na: not assessed; Val: valine.
* Significant.
hippocampal volumes between patients and controls of the same
genotype. The first meta-analysis did not support an association
between hippocampal volumes and the BDNF rs6265 genotype in
neuropsychiatric patients, either for the left, or for the right, or for
the bilateral hippocampus. This finding is of the same magnitude as
found in previous meta-analyses of patients (Kambeitz et al., 2012;
Molendijk et al., 2012a). The present finding in patients, as well
as the negative finding in a recently published meta-analysis in
healthy individuals (Harrisberger et al., 2014), might suggest that
structural hippocampal differences are not primarily dependent
on the BDNF polymorphism in humans. In further meta-analyses,
we investigated the relative hippocampal loss of Val/Val homozy-
gous neuropsychiatric patients versus healthy controls and also
Met-carrier patients versus healthy controls. These meta-analyses
revealed  a significant association of the left, the right and the bilat-
eral hippocampal volumes with the rs6265 polymorphism. It was
confirmed that neuropsychiatric patients had smaller hippocampal
volumes than healthy controls, regardless of the genotype. This
finding corresponds with other studies in major neuropsychiatric
disorders that found smaller hippocampal volumes in patients
(e.g. review Geuze et al., 2005). In this study, however, we were
interested in whether there is a difference in magnitude between
the genotypes. We  found that the reductions in hippocampal
volume in neuropsychiatric patients relative to healthy controls
did not depend on the specific genotype, which suggests that other
factors drive the reductions in hippocampal volume in patients.
Neuropsychiatric patients appeared to have similar hippocampal
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Fig. 2. (A) Forest plot of random effects meta-analysis investigating the association between hippocampal volumes and the BDNF SNP rs6265. Positive effect sizes indicate
larger  hippocampi for Val allele neuropsychiatric patients than Met  allele neuropsychiatric patients. Dashed lines indicate zero line. Square size proportional to sample size.
(B)  Funnel plot of potential bias where trim and fill procedure revealed no missing studies to correct for potential publication bias. (C) Bubble plot of meta-regression analysis
reflecting  the association between year of publication and effect size. Circle size is proportional to the inverse of the variance, and thus to the precision of each study.
hippocampal volume loss was similar for the two  investigated
genotypes in neuropsychiatric patients relative to healthy controls.
This might suggest that the rs6265 SNP is not inherently
involved in the loss of hippocampal volume in neuropsychiatric
patients and that the Met  allele might not be a possible risk allele
(A/Met) for depression and schizophrenia or a protective allele for
bipolar disorder. Further investigation is needed on how this poly-
morphism can affect any reduction in secreted BDNF and what
this means for cellular processing. As reported by several studies,
a promising direction for future work might be the field of gene-
environment (G × E) interaction and also psychopharmacological
interventions. For example, most previous studies investigating
interactions between the BDNF rs6265 and stressful life events,
trauma or childhood abuse indicated smaller hippocampal volumes
in Met-carriers with adversity (Aas et al., 2013; Carballedo et al.,
2013; Frodl et al., 2014; Gatt et al., 2009; Gerritsen et al., 2012; Joffe
et al., 2009; Molendijk et al., 2012b; Rabl et al., 2014). Along this line,
the hippocampal—hypothalamus–pituitary–adrenocortical path-
way and the medial PFC-hippocampal-amygdala pathway may  be
necessary in the regulation of stress (Ninan, 2014; Rosas-Vidal
et al., 2014). Thus hippocampal volume loss and also impairment
of cognitive functions might be associated with decreased BDNF
availability in these pathways, where Val/Val and Met-carriers dif-
fer in coping with stress, thereby exacerbating symptom severity.
Unfortunately, however, we could not evaluate such aspects in
our meta-analysis, as most studies did not report environmental
factors. Furthermore, preliminary results indicate that the BDNF
level is elevated by neuropsychiatric medication and most studies
showed that the treatment response to lithium, citalopram, esci-
talopram or fluoxetine (antidepressants in general) was  more effi-
cient for BDNF Met-carriers (Choi et al., 2006; Dmitrzak-Weglarz
et al., 2008; El-Hage et al., 2014; Rybakowski et al., 2005; Tsai et al.,
2003; Zou et al., 2010), whereas Val/Val homozygotes responded
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Fig. 3. (A) Forest plot of random-effects meta-analyses investigating the association between hippocampal volumes and the BDNF SNP rs6265 in Val/Val homozygote patients
and  healthy controls. Positive effect sizes indicate larger hippocampi for healthy control subjects than neuropsychiatric patients. Dashed lines indicate zero line. Funnel plot of
potential  bias where trim and fill procedure revealed no missing studies to correct for potential publication bias. (B) Forest plot of random effects meta-analyses investigating
the  association between hippocampal volumes and the BDNF SNP rs6265 in Met-carrier patients and healthy controls. Positive effect sizes indicate larger hippocampi for
healthy  control subjects than patients. Dashed lines indicate zero line. Funnel plot of potential bias where white dots indicate the missing studies to correct for potential
publication  bias obtained by trim and fill procedure.
et al., 2014; Hong et al., 2003; Perkovic et al., 2014; Xu et al.,
2010; Zai et al., 2012). This opens up a whole new field of person-
alised medicine/patient treatment. The opposing effects of BDNF
expression in the hippocampus during stress and neuropsychiatric
medication should be further investigated. Another important issue
is whether and how the balance between pro-BDNF and mature
BDNF is affected by the rs6265 polymorphism, bearing in mind that
pro-BDNF promotes cell apoptosis and long-term depression while
mature BDNF supports cell survival and long-term potentiation
(Barde, 1989; Lee et al., 2001; Park and Poo, 2013) at hippocampal
synapses. Some limitations need to be considered. First, the hetero-
geneity detected in the meta-analysis may  have come from other
moderators, such as medication, duration of illness or drug use,
which were unfortunately not available for most studies. Moreover,
the p-values of the meta-analysis were not adjusted for multiple
comparison.  Second, a major limitation of this meta-analysis is that
most original studies were underpowered and this tends to reduce
the power of the meta-analysis. For this reason, the absence of an
association between the BDNF rs6265 genotype and hippocampal
volume must be confirmed by meta-analyses including additional
replication studies, preferably with large datasets. Third, most of
the included studies conducted their research on individuals of
Caucasian origin where the Met/Met variant is normally very rare
(Petryshen et al., 2010) and no comparison with heterozygote indi-
viduals is possible. The only study with an Asian sample (Takahashi
et al., 2008), and thus with a larger proportion of Met/Met homozy-
gotes, did not look into this issue. Fourth, it could not be evaluated
how the known ethnic differences (Petryshen et al., 2010; Shimizu
et al., 2004) would affect the result, as most studies were conducted
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disorders in the reported risk allele might imply different outcomes
for the individual disorders. To investigate this issue, more studies
would be needed for each of these disorders. Finally, differences in
hippocampal sub-regions between rs6265 genotypes might shed
light on the involvement of impaired anatomical connectivity in the
brain. If a sub-region of the hippocampus is altered in volume, the
interrelated cortical and subcortical brain regions, such as the pre-
frontal cortex or amygdala (Ninan, 2014; Rosas-Vidal et al., 2014),
should also be included in further investigations to assess possible
impairments in the network. The present meta-analysis does not
support the existence of BDNF-dependent volume differences in
the hippocampus of neuropsychiatric patients. The significant asso-
ciation between hippocampal volumes and the rs6265 SNP for neu-
ropsychiatric patients versus healthy controls confirms previous
results and does not support the risk hypothesis of the Met-allele.
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Supplementary Figure 1. Barplots showing disorder specific information of A. 
mean bilateral hippocampal volumes [mm3] ± standard deviation of all studies 
reporting these values. The hippocampal volumes did not differ significantly between 
the BDNF rs6265 genotypes of each disorder. We explicitly avoided the comparison 
among the disorders due to only few or even a single published study per disorder 
and also negative results of the meta-regression in the overall meta-analysis. B. the 
BDNF rs6265 genotype frequency. All disorders had similar genotype frequencies. 
BD, Bipolar Disorder; MDD, Major Depressive Disorder; SZ, Schizophrenia;  
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Supplementary Figure 2. Forest plot of random effects meta-analyses investigating 
the difference between: A. hippocampal volumes and the BDNF SNP rs6265 of all 
studies. B. left hippocampal volume and the BDNF SNP rs6265. C. right 
hippocampal volume and the BDNF SNP rs6265. D. left hippocampal volume and 
Val/Val homozygote patients versus healthy controls. E. right hippocampal volume 
and Val/Val homozygote patients versus healthy controls. F. left hippocampal volume 
and Met-carrier patients versus healthy controls. G. right hippocampal volume and 
Met-carrier patients versus healthy controls.  
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3.3 Volumetric subcortical alterations in individuals at high-risk 
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Volumetric hippocampal reductions are a hallmark of schizophrenia and already of 
the clinical high-risk state. A recent study automatically segmented subcortical 
volumes and showed the involvement of several subcortical volumes in 
schizophrenia. We sought to investigate the role of these subcortical volumes 
assessed by automatic segmentation in a multi-center cohort of clinical high-risk 
individuals. 
Clinical high-risk individuals and healthy controls underwent structural MRI 
measurements and thereafter the bilateral volume of seven subcortical brain regions 
were automatically segmented, namely the hippocampus, the thalamus, the caudate, 
the putamen, the pallidum, the amygdala and the accumbens. We then used a linear 
mixed-effects model and prospective meta-analysis to assess group-related 
volumetric differences. 
We report reduced hippocampal and thalamic volume in clinical high-risk individuals 
compared to healthy controls. Moreover, we found comparable medium effect sizes 
for group-related comparison of the hippocampus and the thalamus using two 
different methods. These findings demonstrate that some of the subcortical volumes 
are already altered in the high-risk state. This might suggest that these volumes can be 
used as a very early marker in the prediction of psychosis. 
 
 
Keywords: Hippocampus, Thalamus, Structural, MRI, At-risk mental state, Ultra-






Structural brain alterations assessed with magnetic resonance imaging (MRI) are 
commonly reported in schizophrenia patients. The most replicated findings are an 
increase of ventricle size and reduction of hippocampal volumes 1. Furthermore, 
hippocampal volumetric alterations are already present in subjects at high clinical risk 
for psychosis 2,3. These alterations are therefore present before the onset of psychosis 
and can be studied in clinical high-risk (CHR) individuals with minimal confounding 
effects of medication and disease progression. The high-risk state is of special 
interest, as only around 30% of these individuals will develop psychosis 4–6 and the 
identification of these individuals and early intervention might thus prevent or delay 
transition to psychosis from the CHR state 7,8.  
A recent publication with more than 2000 schizophrenia patients and around 2500 
healthy controls (HC) assessed the subcortical volumes with automated segmentation 
methods 9. They showed in schizophrenia patients that the hippocampus, the 
thalamus, the amygdala and the accumbens were smaller and the pallidum larger 
compared to healthy controls. Smaller hippocampal and larger pallidum volumes 
were already shown by a multi-scanner study applying automated subcortical 
segmentation 10. Both studies applied a prospective meta-analysis procedure, while 
the latter compared it to a univariate mixed model regression analysis. They found 
that the effect sizes of the multisite sample were 13% smaller compared to the 
prospective meta-analysis, a result that indicates between-site variance due to the 
different magnetic resonance imaging (MRI) scanners. Additionally, automated 
segmentation of the subcortical volumes (i.e. hippocampus, thalamus, caudate, 




segmentation with comparable accuracy, sensitivity and reproducibility compared to 
the gold standard of manual segmentation 11–14.  
Through the interconnection with cortical and other subcortical areas, the subcortical 
structures are involved in a variety of tasks. e.g. learning and memory 15, emotional or 
motivational processing 16. Aspects of these neuronal brain circuits are at least in part 
impaired in schizophrenia and already the high-risk state 17,18. Moreover, moderate to 
high heritability of subcortical volumes showed large extended families affected with 
schizophrenia 19. 
To date there has been no investigations of all these subcortical volumes in one 
analysis in the clinical high-risk state for psychosis. Therefore we thought to 
elaborate all subcortical volumes automatically segmented with FSL-FMRIB ‘s 
Integrated Registration and Segmentation Tool 20 in CHR individuals and healthy 
controls (HC) in a combined cohort of from Basel and Zurich. The linear mixed-
model approach account for scanner effects but group comparison requires similar 
effect sizes per site, which reduced the sample sizes drastically. Therefore, we 
additionally performed a prospective meta-analysis with 91 CHR individuals and 64 
HC. Based on previous meta-analyses 2,3, we hypothesized to find smaller 






Material and Methods 
Participants 
For this structural MRI analysis individuals with a prodromal psychosis and healthy 
controls were recruited in two individual centres: In Basel as part of the early 
detection of psychosis research program, FePsy, at the Psychiatry Outpatient 
Department, Psychiatric University Clinics Basel 6,21 and in Zurich as part of a 
prospective study on the early recognition of psychosis 22 within the Zurich Program 
for Sustainable Development of Mental Health Services (ZInEP), conducted at the 
Psychiatric University Hospital, University of Zurich.  
For details of the recruiting process and clinical assessment as well as inclusion and 
exclusion criteria, see Smieskova et al. 23 and Theodoridou et al. 22. 
Briefly, a total of N=94 CHR and N=64 healthy controls from Basel and Zurich were 
recruited (Table 1). 7 CHR individuals received already at the time of scanning 
antipsychotic-medication and 15 received antidepressants. In addition, a subgroup 
was selected to have equal numbers of CHR individuals and HC per scanner. This 
resulted in N=45 CHR individuals and N=43 HC (Table 2). All individuals of the 
smaller sample were antipsychotic-naïve at the time of scanning whereas 15 of the 
CHR were receiving antidepressants. 
All participants provided written informed consent, and the studies had research 
ethics committee permission. 
 
MRI acquisition 
Basel: All anatomical scans were performed on a 3 T scanner (Siemens Magnetom 




weighted MPRAGE sequence was used with the following parameters: an inversion 
time of 1,000 ms (θ =8 degrees), TR = 2 s, TE = 3.37 ms, FOV = 25.6 cm, acquisition 
matrix = 256 x 256 x 176, resulting in 176 contiguous sagittal slices with 1x1x1 mm3 
isotropic spatial resolution. All scans were screened by an experienced 
neuroradiologist for radiological abnormalities. 
Zurich: Structural MRI data were acquired on a Philips Achieva TX 3-T whole-body 
MR unit, using an 8-channel head coil. Three-dimensional T1-weighted images of the 
whole brain were acquired (FFE pulse sequence, TR = 8.3 ms, TE = 3.8 ms, flip-
angle 8 degree, FOV 240x240 mm2, voxel size 1x1x1 mm3 (reconstructed: 
0.94x0.94x1 mm3), 160 contiguous slices). An experienced neuroradiologist screened 
all structural MRI images to check for organic abnormalities. 
 
Image processing 
Volumetric segmentation of subcortical structures were estimated on T1-weighted 
MPRAGE images using FMRIB ‘s Integrated Registration and Segmentation Tool 
5.0.4 (FSL-FIRST) 20. All seven structures (accumbens, amygdala, caudate, 
hippocampus, pallidum, putamen, thalamus) were obtained for both hemispheres. To 
account for non-gaussian volume distribution, the cube root of all volumes was 
calculated. Then, the volumes were normalised with the cube root of the intracranial 
volume (ICV) and mean-centered for each site separately, to correct for different 
intensities measured between sites. After an outliers control (mean ± 3.5 SD), these 







The R 3.0.2 software (R Core Team, 2012) 24 and the packages lme4 25 and lmerTest 
26 were used for statistical, group-related analysis. We employed a linear mixed-
effects (LME) model to assess the relationship between group affiliation and each 
subcortical volume with left and right volumes combined in one model as separate 
input. As fixed effects, diagnosis and site information with interaction terms were 
entered, as well as age and gender. As random effect, intercepts for subject and 
hemispheric information were included. Visual inspection of residual plots did not 
reveal a deviation from homoscedasticity or normality. The significance threshold 
was set to p < 0.0071 to correct for multiple comparison (two-tailed).  
 
Prospective meta-analysis 
Data were entered into an electronic database and quantitative meta-analysis was 
performed using the R 3.0.2 software (R Core Team, 2012). The effect size was 
calculated using Hedge’s g, which provides an unbiased standardized mean difference 
that incorporates a correction for small sample sizes 27. Hedge’s g values above 0.5 
correspond to medium effect sizes. Hedge’s g was calculated using data of mean 
hippocampal volumes, standard deviations and sample sizes. A positive value of the 
effect size reflected larger volumes for HC than for CHR individuals. We employed a 
random-effects model with the DerSimonian-Laird estimator using the metafor 







Statistical analysis of clinical and socio-demographic data 
One-way ANOVAs and chi-square tests were used to test the distribution between 
diagnosis group and age, sex, handedness, years of education, IQ, positive symptoms 
cluster, negative symptoms cluster, each single item of these clusters, GAF, scanner 
and ICV. Basel and Zurich have used different scales for measuring psychotic 
symptoms. We combined several items of the BPRS with the PANSS outcomes into a 
positive (BPRS9, BPRS10, BPRS11, BPRS15 and PANSS P2, PANSS P3, PANSS 
P6, PANSS G9) and a negative (BPRS16, BPRS17, BPRS18 and PANSS N1, 
PANSS N2, PANSS G7) symptom cluster according to Lyne et al. 29. These statistical 
analyses were performed with R 3.0.2 software (R Core Team, 2012). Values are 
presented as mean ± SD (see table 1). In addition, associations between subcortical 
volumes and clinical symptoms (positive and negative symptom clusters and global 






Clinical and demographic characteristics 
There were no significant differences among our groups with respect to gender (p = 
0.20), handedness (p = 0.99) and site (p = 0.58). There were significant between-
group differences in age (p = 0.02), education (p < 0.0001), IQ (p = 0.04), positive (p 
< 0.0001) and negative symptom cluster (p < 0.0001) and global functioning (GAF) 
(p < 0.0001) (Table 2). 
In the larger cohort there were no significant differences with respect to gender (p = 
0.14), handedness (p = 0.68) and IQ (p = 0.08). There were significant between-group 
differences in age (p = 0.03), education (p = 0.0002), positive (p < 0.0001) and 
negative symptom cluster (p < 0.0001) and global functioning (GAF) (p < 0.0001) 
and site (p < 0.0001) (Table 1). Among the high-risk individuals no significant 
correlation was detected between any of the significant subcortical volumes and 
psychopathological measures. 
 
Table 1, Table 2 here 
 
Subcortical volume differences 
Significant group effects were detected for the volumes of the hippocampus (F = 
11.13, p = 0.001, Table 3 and g = -0.68, se = 0.22, Z = -3.11 p = 0.002, 95%CI = [-
0.25 – -1.12]) and the thalamus (F = 7.74, p = 0.0066, Table 3 and g = -0.67, se = 
0.22, Z = -3.04, p = 0.002, 95%CI = [-0.23 – -1.1]). High-risk individuals showed 
significant smaller volumes compared to HC. These results are multiple comparison 




(two-tailed). Moreover, there were significant effects of gender on hippocampal 
volumes. In addition, we performed a meta-analysis of the regions with significant 
group differences (i.e. hippocampus and thalamus) within a larger cohort (n=158; 
including the above individuals). These meta-analyses showed again smaller volumes 
for CHR compared to HC for both regions (Hippocampus: g = -0.52, se = 0.18, Z = -
2.89, p = 0.004, 95%CI = [-0.88 – -0.17], Q(df = 2) = 0.23, p = 0.89; Thalamus: g = -
0.64, se = 0.18, Z = -3.49, p = 0.0005, 95%CI = [-0.99 – -0.28], Q(df = 2) = 0.10, p = 
0.95, Figure 1). 
 







We analysed volumetric subcortical differences between antipsychotic-naïve 
individuals at clinical high risk for psychosis and healthy controls. We found 
significant smaller volumes of the hippocampus and the thalamus in CHR individuals 
compared to HC. And no between-group difference was observed between the 
volumes of the caudate, putamen, pallidum, amygdala and accumbens. The further 
comparison of the significant different volumes determined by LME models with 
results from prospective meta-analyses within a larger cohort revealed comparable 
medium effect sizes for the thalamus. However, the results for the hippocampal 
volumes differed slightly, though both detected medium effect sizes.  
In line with a recent study of subcortical volumes in schizophrenia patients and the 
current meta-analyses in CHR populations 2,3, we could replicate smaller 
hippocampal volumes for CHR individuals compared to HC. Moreover, we could 
increase the findings of an influence of thalamic volumes in the CHR state. Then, 
structural thalamic reduction were recently shown in a CHR cohort 30, as well as in 
schizophrenia 31 and especially in antipsychotic-naïve patients 1. As both applied 
methods revealed significant differences in volume between CHR individuals and 
HC, we might speculate that the inclusion of 7 antipsychotic-treated individuals in the 
larger cohort, did not have a influential effect on these results. It was speculated that 
these two structures and their interconnection might be involved in a mechanism for 
the sudden onset of schizophrenia 32, which definitively needs further investigation. 
In our analysis the different image acquisition modalities (generally higher image 
intensities measured in Zurich) lead to differences in the segmentation of the 




before group-related comparison although this reduced the sample size drastically. In 
addition, we performed a prospective meta-analyses, as proposed by the ENIGMA 
consortium 9,10,33, which is an elegant way for group-related comparison from 
different sites. However, we must account that a meta-analysis with only three 
included studies is not very powerful. Nevertheless, we obtained similar results with 
the meta-analytic approach and the LME model.  
Future research should also investigate the association of common genetic variants on 
subcortical brain volumes in CHR populations, as it was shown that genetic 
components can influence the volumes of the subcortical structures in healthy 
humans 34–36.  
Altogether, we found smaller hippocampal and thalamic volumes in CHR individuals 
compared to HC individuals with two different comparison methods. These findings 
demonstrate that some of the subcortical volumes are already altered in the high-risk 
state. Moreover, we found comparable medium effect sizes for both structures 
assessed with both methods. This might suggest that these volumes and the 
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Figure 1: Forest plot of prospective, random effects meta-analyses investigating the 
difference between: A. hippocampal volumes and group affiliation rs6265 of all 
studies. B. thalamic volumes and group affiliation. Negative values represent smaller 








 33.05%    -0.70 [ -1.32 , -0.08 ]
 12.32%    -0.52 [ -1.54 ,  0.50 ]
 54.63%    -0.62 [ -1.10 , -0.14 ]
100.00%    -0.64 [ -0.99 , -0.28 ]







 33.25%    -0.56 [ -1.17 ,  0.06 ]
 11.89%    -0.73 [ -1.75 ,  0.30 ]
 54.87%    -0.46 [ -0.94 ,  0.02 ]
100.00%    -0.52 [ -0.88 , -0.17 ]
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Alterations in hippocampal volume are a known marker for first-episode psychosis as 
well as for the clinical high-risk states. The polygenic schizophrenia-related risk 
score, derived from a large case-control study, indicates the polygenic predisposition 
for schizophrenia in our clinical sample.  
Objectives 
To investigate whether the association between hippocampal volumes and the onset 
of psychosis is modulated by a polygenic schizophrenia-related risk score. 
Design 
Linear and logistic regression of the polygenic schizophrenia-related risk score and 
hippocampal volume data in individuals with an at-risk mental state for psychosis and 
first-episode psychosis patients. 
Setting 
Participants were recruited through the specialised service for the early detection of 
psychosis at the Department of Psychiatry, University of Basel, Basel, Switzerland. 
Participants 
Thirty-eight individuals with an at-risk mental state (mean [SD] age, 23.83 [4.31] 
years) and twenty-seven first-episode psychosis patients (mean [SD] age, 28.33 
[7.91] years). 
Main Outcome and Measures 
Automatic segmentation of hippocampal volumes derived from T1-weighted 




polygenic schizophrenia-related risk score, based on the publicly available top single 
nucleotide polymorphisms from the Psychiatric Genomics Consortium GWAS. 
Results 
We observed a negative association between the polygenic schizophrenia-related risk 
score and hippocampal volumes (R2 = 0.11, p = 0.01, 95%CI = [-0.54 – -0.10]) across 
first-episode psychosis patients and at-risk mental state individuals. Moreover, a 
higher polygenic schizophrenia-related risk score was significantly associated with a 
higher probability of an individual being assigned to the first-episode psychosis group 
relative to the at-risk mental state group (β = 0.64, p = 0.03, 95%CI = [0.08 – 1.29]). 
Conclusion and Relevance 
A subset of schizophrenia risk variants is negatively associated with hippocampal 
volumes and higher values of this polygenic schizophrenia-related risk score are 
significantly associated with first-episode psychosis compared to the at-risk mental 
state. These findings imply that FEP patients have a higher genetic risk for 
schizophrenia than the total cohort of ARMS individuals. The identification of 
associations between genetic risk variants and structural brain alterations will 
increase our understanding of the neurobiology underlying the transition to psychosis. 
 
Keywords: Hippocampus, Hippocampal Volumes, Structural, MRI, At-Risk Mental 





Schizophrenia can be a severe mental disorder, affecting around one percent of the 
population 1. Although the pathophysiological mechanisms underlying schizophrenia 
are still poorly understood, it is known that genetic factors and combinations thereof 
(i.e. single nucleotide polymorphisms, copy-number variations or mutations) are 
involved in disease aetiology, as is indicated by the substantial heritability estimates 
for schizophrenia 2. And whether an individual will make the transition to psychosis 
from the clinical high-risk state also presumably depends on the presence of different 
environmental trigger-factors. Around 30% of clinical at-risk mental state (ARMS) 
individuals will make a transition to psychosis within the subsequent two years 3–5. 
Finding markers that further characterise these ARMS individuals is a main goal of 
psychiatric research, as early treatment of this group is thought to prevent or delay the 
onset of a first episode of psychosis 6,7. Several markers besides clinical 
characteristics describe prodromal psychosis, for example, structural and functional 
brain alterations or cognitive functioning. Even in the ARMS, neuroimaging 
observations revealed reductions in the grey matter of the medial temporal lobe, 
including the hippocampus 8–12, as well as neurofunctional aberrations within the 
hippocampus 13 and deficits in verbal fluency and memory functioning 14. However, 
results are inconsistent on the differences in hippocampal volume between first-
episode of psychosis (FEP) patients and ARMS individuals, regardless of future 
transition to psychosis 8,9,15. Moreover, hippocampal volumes were shown to be 
highly heritable in twin studies of healthy individuals 16,17, but twin studies where one 
of the twins was affected by schizophrenia also revealed substantial modulation of 




heritability of the hippocampal volumes was shown in large extended families 
affected with schizophrenia 22.  
Although individual effects of single nucleotide polymorphisms (SNPs) on the 
genetic risk for schizophrenia were found to be small, it was estimated that 23% of 
variation in liability to schizophrenia is captured by SNPs with a substantial 
proportion of this variation attributed to common causal variants 23,24. The largest 
genome-wide association study (GWAS), performed by the Psychiatric Genomic 
Consortium (PGC), identified 108 schizophrenia-associated loci 25, which explained 
up to 3.4% of the phenotypic variance in case-control studies. In general, the 
combination of GWAS-significant risk SNPs, the polygenic schizophrenia-related 
risk score (PSRS), describes the estimated cumulative genomic risk for 
schizophrenia.  
Only a few studies have reported associations between a PSRS and brain volumes. 
All of these studies investigated the above mentioned association in different cohorts 
of schizophrenia patients, their relatives and/or healthy controls 26–28. They found 
association of a PSRS with total brain volume 26, especially with white matter volume 
26,27. Unfortunately, these results could not be replicated in another independent 
sample 28. However, none of these studies investigated the association of a PSRS with 
brain volume in ARMS individuals and FEP patients. Moreover, a GWAS identified 
single SNPs linked to hippocampal volume in healthy controls 16, but no study to date 
has investigated the association of a PSRS with volumetric differences in this region.  
On the basis of findings supporting a role for hippocampal alterations in FEP and 




hippocampal volume and the onset of psychosis. The identification of associations 
between genetic risk variants and structural alterations will increase our 
understanding of the neurobiology underlying psychosis, as well as the transition to 
psychosis. Linking the PSRS to structural alterations in the brain will be helpful in 
elucidating the neurobiology underlying psychosis and may also increase our 
understanding of the factors contributing to the transition to psychosis in ARMS 
individuals. We hypothesised that a higher PSRS is associated with both smaller 





Participants and clinical assessment 
Individuals included in this study were recruited via the early detection of psychosis 
research program at the Psychiatry Outpatient Department, Psychiatric University 
Clinics Basel 5,29 and were either ARMS individuals or FEP patients. All individuals 
were assessed by the Basel Screening Instrument for Psychosis (BSIP) 30, the Brief 
Psychiatric Rating Scale (BPRS), the Scale for the Assessment of Negative 
Symptoms (SANS) and the Global Assessment of Functioning (GAF), at the time of 
the MRI scan. We additionally obtained information on current and previous 
psychotropic medication, nicotine, and illegal drug consumption using a semi-
structured interview adapted from the Early Psychosis Prevention and Intervention 
Centre Drug and Alcohol Assessment Schedule (eppic.org.au). 
 
ARMS was defined in accordance with the criteria by Yung and resulted in the 
inclusion of N = 43 ARMS individuals in the study 31. Thus, inclusion required one or 
more of the following: (a) ‘‘attenuated’’ psychotic symptoms, (b) brief limited 
intermittent psychotic symptoms, or (c) a first- or second-degree relative with a 
psychotic disorder plus at least two indicators of a clinical change, according to the 
BSIP 29,32. Inclusion because of criterion (a) required a change in mental state at least 
several times a week and for more than 1 week (a score of 2 or 3 on the BPRS 
hallucination item or 3 or 4 on BPRS items for unusual thought content or 
suspiciousness). Inclusion due to (b) required BPRS scores of ≥ 4 on the hallucination 




disorganisation items, with each symptom lasting less than 1 week before resolving 
spontaneously. None of the included subjects fulfilled criterion (c). All individuals 
were antipsychotic-naïve at the time of scanning whereas 18 of the ARMS 
individuals were receiving antidepressants.  
The FEP patients (N = 36) met the operational criteria according to Breitborde et al. 
33 and they fulfilled criteria for acute psychotic disorder according to ICD-10 or 
DSM-V but not for schizophrenia. Inclusion required scores of ≥ 4 on the 
hallucination item or ≥ 5 on the unusual thought content, suspiciousness or 
conceptual disorganisation items of the BPRS. The symptoms had to have occurred at 
least several times a week and persisted for more than 1 week. 14 of our FEP patients 
were antipsychotic-naïve, 3 were antipsychotic-free and 10 were receiving 
antipsychotic medication at the time of scanning (three quetiapine, three risperidone, 
two olanzapine, one clozapine, one aripiprazole). In the antipsychotic-free group 
antipsychotic medication (two risperidone, one aripiprazole) has been stopped 4, 19 
and 24 months previously. Antipsychotic dose was converted into chlorpromazine 
(CPZ) equivalents using the supplementary table ‘Antipsychotic dose conversion’ by 
Ho et al. 34. The mean chlorpromazine equivalents (standard deviation) were 227.39 









The following exclusion criteria were applied for both groups: history of previous 
psychotic disorder, psychotic symptomatology secondary to an ‘organic’ disorder, 
psychotic symptoms associated with an affective psychosis or a borderline 




Classification of Diseases, 10th Revision (ICD-10) research criteria, head trauma, 
neurological illness, serious medical or surgical illness, being younger than 18 years, 
inadequate knowledge of the German language, and IQ less than 70 as measured by 
the Mehrfachwahl Wortschatz [Multiple Choice Vocabulary] Test Form B (MWT-B). 
All participants provided written informed consent, and the studies had permission 
from the ethics committee. 
 
MRI acquisition 
All anatomical scans were performed on a 3T magnetic resonance imaging (MRI) 
scanner (Siemens Magnetom Verio, Siemens Healthcare, Erlangen, Germany) using a 
12-channel phased-array radio frequency head coil. For structural images, a 3D T1-
weighted magnetisation prepared rapid gradient echo (MPRAGE) sequence was used 
with the following parameters: an inversion time of 1,000 ms, flip angle = 8 degrees, 
TR = 2 s, TE = 3.37 ms, FOV = 25.6 cm, acquisition matrix = 256 x 256 x 176, 
resulting in 176 contiguous sagittal slices with 1x1x1 mm3 isotropic spatial 
resolution. All scans were screened for gross radiological abnormalities by an 
experienced neuroradiologist. 
 
Genotyping and Imputation 
DNA was extracted from whole blood samples using the QIAamp® DNA Blood Maxi 
kit according to standard procedures (Qiagen Inc., Chatsworth, CA). DNA samples 
were further processed on the Affymetrix® Genome-Wide Human SNP Array 6.0. in 




Nsp/Sty 6.0. User Guide (Affymetrix, Santa Clara, CA, USA). Generation of SNP 
calls and array quality control were performed using the Affymetrix Genotyping 
Console Software 3.0 (Affymetrix Inc.). According to the manufacturer’s 
recommendation, contrast quality control (QC) was chosen as QC metric, using the 
default value of 0.4. All samples passing QC criteria were subsequently genotyped 
using the Birdseed (v2) algorithm, leading to a total of 921 523 genotyped SNPs per 
sample. Appropriate SNP QC filtering was applied in PLINK 1.9 software 35,36, 
where the gender check in PLINK led to the exclusion of 3 individuals.  
Population stratification was assessed using principal component analysis 
implemented in the EIGENSTRAT software 37 to detect genotypic outliers (with 
default parameters: >6 standard deviations on any of the top ten principal components 
(PC) in five iterations) and correct for potential population substructure by analysing 
all array-based pruned, autosomal SNPs. Eight individuals were identified as outliers 
and therefore excluded from further analyses.  
Imputation was performed with IMPUTE2 38, which aligns SNPs between haplotype 
and genotype databases on the basis of base-pair position, using the 1000 Genomes 
Project (www.1000genomes.org) as reference panel. Inclusion and subsequent 
analysis of an imputed SNP was set to proper info > 0.9. 
 
PSRS calculation 
PSRS were calculated, following the suggestions by Wray et al. 39, by taking LD 
pruned loci identified by the Schizophrenia Working Group of the Psychiatric 




075 healthy controls 25 (http://www.med. unc.edu/pgc/downloads). A total of 87 
SNPs that could be mapped to one of the top SNPs of the 108 loci associated with 
schizophrenia and survived quality control was used to calculate the PSRS. (Included: 
18 SNPs represented on the Affymetrix 6.0 Genotyping Array and 69 imputed SNPs. 
Excluded: 7 SNPs could not be imputed, 3 SNPs on allosome, 11 Insertion/Deletion 
variants, 20 variants in physically dependent genomic regions.) In summary, the 
number of risk alleles per person was weighted for each SNP by the logarithm of its 
odds ratio as reported in the PGC SZ dataset 25 and summed across SNPs 40 using the 
PLINK 1.9 software 35,36. The PSRS was then corrected for the first twenty genotypic 
PCs and the number of SNPs used to calculate the PSRS by using the z-transformed 
residuals of a linear regression. 
 
Image processing 
Subcortical structures were segmented from T1-weighted MPRAGE images with 
FMRIB ‘s Integrated Registration and Segmentation Tool 5.0.4. (FSL-FIRST) 41. 
Raw volumes for the left and right hippocampus were extracted and separately 
corrected for intracranial volume (ICV), age, gender antidepressant intake and CPZ 
equivalents by using the z-transformed residuals of a linear regression. After a 
separate outlier control for both hippocampal sides (mean ± 3.5 SD), which resulting 








The R 3.0.2 software 42 with the packages stats was used for statistical, group-related 
analysis. Chi-square tests or t-tests were used to test the distribution between 
diagnosis group and age, sex, handedness, years of education, IQ, BPRS, SANS, 
GAF, antipsychotics, antidepressants, cannabis consumption and smoking. Values are 
presented as mean ± SD (see table 1). In addition, associations between clinical 
symptoms and PSRS or hippocampal volumes were examined with Pearson 
correlation. The relationship between PSRS (corrected for the first twenty genotypic 
PCs and the number of SNPs used to calculate the PSRS) and the bilateral 
hippocampal volumes (corrected for ICV, age, gender antidepressant intake and CPZ 
equivalents) was assessed by Pearson’s correlation. We then fitted a logistic 
regression using the generalised linear model function in R with diagnosis status as 
binary dependent variable and the corrected bilateral hippocampal volumes and the 





Clinical and demographic characteristics 
There were no significant differences among the investigated groups with respect to 
gender (p = 0.83), handedness (p = 0.11), years of education (p = 0.96) MWT-B (p = 
0.74), SANS (p = 0.27) and number of individuals treated with antidepressants (p = 
0.14). There were significant between-group differences in age (p = 0.01), BPRS (p = 
0.001), GAF (p = 0.009) and the number of patients treated with antipsychotics (p < 
0.001) (Table 1). None of the clinical characteristics was associated with the PSRS or 
the hippocampal volumes at the time of MR scanning.  
Table 1 here 
 
Association between diagnosis, PSRS and hippocampal volume 
Pearson’s correlation analysis revealed a significant relationship between the PSRS 
and hippocampal volumes (R2 = 0.11, p = 0.01, 95%CI = [-0.54 – -0.10]) in our total 
sample and the subgroup of ARMS individuals (R2 = 0.14, p = 0.02, 95%CI = [-0.62 
– -0.06], Figure 1) and FEP patients separately (R2 = 0.14, p = 0.05, 95%CI = [-0.66 
– 0.005], Figure 1). To further analyse this association in the total sample, we 
performed a logistic regression analysis. A significant main effect of the PSRS on the 
log odds of an individual being assigned to the FEP state was observed (β = 0.64, p = 
0.03, 95%CI = [0.08 – 1.29], Table2, Figure 2). In addition, neither a main effect of 
the hippocampal volumes (β = 0.59, p = 0.11, 95%CI = [-0.11 – 1.36], Table2) nor an 
interaction effect of PSRS and hippocampal volumes (β = -0.14, p = 0.70, 95%CI = [-




associated with a higher likelihood that an individual would be assigned to the group 
of FEP individuals than to the group of ARMS individuals. 





To our knowledge, this is the first study to analyse the association between a 
polygenic schizophrenia-related risk score, hippocampal volumes and the onset of 
psychosis. We found a negative association between the hippocampal volumes and 
the PSRS across ARMS individuals and FEP patients, derived from the top hits 
within genome-wide significant loci identified by the large GWAS analysis from the 
Psychiatric Genomics Consortium 25. Moreover, a higher PSRS was significantly 
associated with a higher probability of being assigned to the FEP group than to the 
ARMS group. 
We demonstrate that reduced hippocampal volumes were associated with higher 
PSRS in the total sample of ARMS individuals and FEP patients as well as for each 
group separately. This association might suggest that schizophrenia-related SNPs are 
directly linked to smaller hippocampi. However, such a direct link cannot be inferred 
from our results, because other factors like stressful life events 43 or neuropsychiatric 
medication 44,45 have been shown to modulate the volumes of the hippocampus. It 
should be further noted that volumetric alterations in the hippocampus have been 
linked to psychotic symptoms and cognitive deficits of schizophrenia 46, a core 
function of the hippocampus, and ARMS individuals already show some deficits in 
verbal fluency and memory functioning 5,14. 
We also observed that a higher PSRS was associated with a higher likelihood of an 
individual being assigned to the FEP group than to the ARMS group. This finding 
might reflect the fact that only around 30% of ARMS individuals are correctly 
predicted to develop psychosis 4,5 and thus might not have a high PSRS. Therefore, 




those ARMS individuals who will develop psychosis and whether ARMS individuals 
with a higher PSRS are more likely to develop psychosis. Due to the limited number 
of ARMS individuals with later transition to psychosis, we could not investigate 
whether this PSRS might be a vulnerability trait for transition. Nevertheless, we 
observed that four of our six ARMS individuals who (until now) have developed 
psychosis had a PSRS above the median of the total sample. Therefore, further 
longitudinal studies should examine whether a combination of clinical, genetic, 
environmental, neuroimaging and neurocognitive markers can improve the prediction 
rate for transition to psychosis. 
The absence of a significant association between hippocampal volumes and being in 
either the ARMS or FEP groups supports several findings of similar volumes 8,9,15. 
Furthermore, it has been reported that the volumes of the hippocampus were 
negatively associated with negative symptoms in ARMS individuals and 
schizophrenia patients 47–50 and that the hippocampal-prefrontal pathway was linked 
to negative symptoms and cognitive deficits in schizophrenia 51. Therefore, it might 
be speculated that the similar levels of negative symptoms in FEP patients and 
ARMS individuals might partially underlie the absence of volumetric hippocampal 
differences. However, future functional and structural connectivity studies should 
further examine the hippocampus and the interrelated cortical and subcortical regions, 
including the dorsolateral prefrontal cortex, to assess possible impairments in 
neuronal networks in schizophrenia. 
There are some limitations to bear in mind concerning the results of this study. First, 
the sample size is relatively small. However, the groups are homogeneous with regard 




prognosis 52. This makes confounding effects of disease duration or antipsychotic 
medication unlikely. In addition, polygenic risk scores derived from large GWAS 
generate robust estimators 53 which can be used in small samples. Second, the PSRS 
explains only a small amount of variance in liability to schizophrenia and cannot be 
considered as a classifier between ARMS individuals and FEP patients. Thus, 
prediction of actual transition to psychosis is not possible, but this aspect will be 
further investigated when we have obtained enough follow-up data.  
In summary, this is the first study to evaluate a negative association between a PSRS 
and hippocampal volumes in ARMS individuals and FEP patients. Our findings 
suggest that the combination of a subset of schizophrenia risk variants is related to 
hippocampal volume and that higher values of this genome-wide significant PSRS 
(but not hippocampal volume or the interaction effect) are associated to FEP status 
than to the ARMS. These findings imply that FEP patients have a higher genetic risk 
for schizophrenia than the total cohort of ARMS individuals and encourage further 
studies on the use of RSPS as an additional marker in the prediction of psychosis 
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Figure 1. Linear Regression Analyses of Polygenic Schizophrenia-Related Risk Score 
and Hippocampal Volumes 
 
Standardised residuals of the mean hippocampal volume are adjusted on each side 
separately for ICV, age, gender antidepressant intake and CPZ equivalents. 
Standardised residuals of the PSRS are adjusted for the first twenty genotypic PCs 
and the number of SNPs used to calculate the PSRS. Red dotted line: Regression line 
with 95% confidence interval of FEP cohort; Blue dotted line: Regression line with 
95% confidence interval of ARMS cohort. 
ARMS_NT: At-risk mental state individuals without transition to psychosis, 
ARMS_T: At-risk mental state individuals with subsequent transition to psychosis; 
CPZ: Chlorpromazine; FEP: First-episode psychosis patients; ICV: Intra-cranial 
volume; PCs: Principal components. 
  

































Figure 2. Plot of Estimated Probability for being FEP versus Polygenic 
Schizophrenia-Related Risk Score 
 
The standardised residuals of the PSRS are adjusted for the first twenty genotypic 
PCs and the number of SNPs used to calculate the PSRS are plotted against estimated 
probability of logistic regression. Black dotted line: Regression line of FEP and 
ARMS cohort;  
ARMS_NT: At-risk mental state individuals without transition to psychosis, 
ARMS_T: At-risk mental state individuals with subsequent transition to psychosis; 









































I investigated throughout this thesis the role of the hippocampal volumes in the 
developing disorder, especially for FEP patients and ARMS individuals and selected 
genetic risk markers associated with schizophrenia. Specifically, we analyzed in 
chapter 3.1 the relation of the BDNF rs6265 polymorphism to the volumes of the 
hippocampus in healthy individuals, in original data and by meta-analysis to obtain a 
basis for the potential association. We further examined by meta-analysis whether 
this association is present in neuropsychiatric patients in chapter 3.2. Moreover, the 
volumetric subcortical alterations including the hippocampus in ARMS individuals 
compared to HC were determined in chapter 3.3. And last, the association between a 
PSRS and the hippocampus in a cohort of ARMS individuals and FEP patients was 
assessed in chapter 3.4. 
Our findings do not support the association between the BDNF rs6265 polymorphism 
and hippocampal volumes neither in original data of HC, the meta-analysis with HC 
nor in the meta-analysis with neuropsychiatric patients. In detail, the meta-analysis 
with HC showed a weak effect that was mainly powered by early studies using 
manual hippocampal segmentation in combination with small sample sizes. In 
contrast, the meta-analysis with automated segmentation of the hippocampus revealed 
no association. Therefore, not only publication year and sample size can influence 
meta-analytic results but also measuring techniques need to be taken into account.  
The meta-analysis with neuropsychiatric patients also showed no association between 
the BDNF rs6265 polymorphism and hippocampal volumes.  Moreover, we could 
replicate smaller hippocampal volume findings for neuropsychiatric patients 
compared to HC and this reduction is comparable for Val/Val homozygote or Met-
carriers, meaning that neither Val or Met is a risk or a protective allele for volumetric 
hippocampal alterations in neuropsychiatric disorders.  
Next, the subcortical volume analysis demonstrated smaller hippocampal and 
thalamic volumes for ARMS individuals compared to HCs. Moreover, we found 
comparable medium effect sizes for group-related comparison of the hippocampus 
and the thalamus using two different methods.  
Finally, we could show that a PSRS of GWAS-significant, schizophrenia-associated 
SNPs was negatively associated with hippocampal volume in ARMS and FEP 
patients and a higher PSRS was associated with a higher likelihood of an individual 




We found further evidence for the role of the hippocampus in health and disease, 
especially in ARMS individuals and FEP patients. First of all, we could replicate the 
findings of smaller hippocampal volumes in a cohort of ARMS individuals compared 
to HC in chapter 3.3. And by meta-analysis we demonstrated smaller hippocampal 
volumes for neuropsychiatric patients, including schizophrenia in chapter 3.2. These 
results are in line with many studies of reduced hippocampal volumes in 
schizophrenia, FEP and the ARMS compared to HC (e.g. meta-analyses by (Adriano 
et al., 2012; Fusar-Poli et al., 2012c; Haijma et al., 2013; Shepherd et al., 2012; Steen 
et al., 2006; Vita et al., 2006; Wright et al., 2000)). In contrast, we found no 
difference in hippocampal volumes between FEP patients and ARMS individual in 
chapter 3.4. A result that further lines up to the inconsistent literature of hippocampal 
volumetric differences between FEP patietns and ARMS individuals (Fusar-Poli et 
al., 2014, 2012c; Smieskova et al., 2010), implying more replication studies. These 
findings make the hippocampus an excellent marker for schizophrenia, FEP and the 
ARMS, but maybe not for the transition to psychosis.  
Moreover, we further investigated the hippocampus volume in association with 
genetic variants related to the susceptibility for schizophrenia. Our findings in chapter 
3.1 and chapter 3.2 suggest no direct association of BDNF rs6265 polymorphism and 
hippocampal volumes. This shows the importance and the power of meta-analytic 
procedures. And also a preliminary analysis with our ARMS and FEP cohort showed 
no significant association between the BDNF rs6265 polymorphism and hippocampal 
volumes (results not shown; p=0.08, p=0.16, respectively). However, most gene-
environment interaction studies indicate smaller hippocampal volumes for Met-
carriers with stressful life events (Aas et al., 2013; Carballedo et al., 2013; Frodl et 
al., 2014; Gatt et al., 2009; Gerritsen et al., 2012; Joffe et al., 2009; Molendijk et al., 
2012; Rabl et al., 2014). And in addition this BDNF SNP might modulate 
hippocampal activation during memory paradigms (Cerasa et al., 2010; Dennis et al., 
2011; Egan et al., 2003; Hariri et al., 2003; Hashimoto et al., 2008; Kambeitz et al., 
2012; Molendijk et al., 2012). Therefore, the role of BDNF in schizophrenia should 
be further investigated. And in chapter 3.4 we showed for the first time an association 
of the hippocampal volumes with a PSRS in our cohort of ARMS individuals and 
FEP patients. Highly speculative, a higher PSRS and lower hippocampal volumes 
might be associated with severe cognitive impairment, thus worse outcome. In 
addition, higher values of the PSRS were associated with a higher probability of an 
individual being assigned to the group of FEP patients compared to the group of 
ARMS individuals. These findings might suggest that FEP patients have a higher 




that only around 30% ARMS individuals are correctly predicted to develop psychosis 
(Fusar-Poli et al., 2012a; Riecher-Rössler et al., 2009). This encourages the use of the 
RSPS as an additional marker in the prediction of psychosis from the prodromal state.  
4.2 Limitations 
Several limitations should be noted along this thesis. All publications from chapter 
3.1 to 3.4 measured brain volume changes using neuroimaging methods. Thus, no 
direct pathophysiological impact, like defects in synaptic transmission or neuronal 
cell loss, can be inferred. Moreover, the number of participants in the original 
publications is relatively small. This might result in limited power of the studies and 
generalizability of the findings. However, the studied group are homogeneous with 
regard to genetic background and clinical characteristics related to disease status. 
This makes confounding effects of disease duration or antipsychotic medication 
unlikely. Next, this PSRS was calculated with most of the 108 schizophrenia-
associated SNPs identified by the PGC (Schizophrenia Working Group of the 
Psychiatric Genomics Consortium, 2014). Nevertheless, it is not given that these are 
the affected genes nor that these SNPs might be the causative SNPs, as the identified 
association is only directing to the involved loci. Furthermore, the PSRS explains 
only a small amount of variance in susceptibility to schizophrenia and cannot be 
considered as a classifier between ARMS individuals and FEP patients. Thus, 
prediction of actual transition to psychosis is not possible, but this aspect will be 
further investigated when we have obtained enough follow-up data. In general, the 
majority of susceptibility to schizophrenia cannot be explained by common genetic 
variants. Therefore, it is more likely that gene-gene interactions (Mackay, 2014) and 
corresponding altered biochemical pathways and epigenetic factors (Dempster et al., 
2013) might account for the missing heritability. And besides genetic predisposition, 
neuropsychiatric medication and environmental factors such as stressful life events 
can modulate gene pathways and neuronal networks.  
4.3 Conclusion 
Overall, we could show the absence of an association between the volumes of the 
hippocampus and the BDNF rs6265 polymorphism in HC and in neuropsychiatric 
patients in chapter 3.1 and chapter 3.2. Moreover, we could replicate the findings of 
volumetric hippocampal reduction in ARMS individuals compared to HC in chapter 




hippocampal volumes and a PSRS in our cohort of ARMS individuals and FEP 
patients. In addition, we could show that higher values of this PRSR are associated 
with a higher probability of an individual being assigned to the FEP group compared 
to the ARMS group, in chapter 3.4.  
Altogether, future research should further investigate the early disease states, which 
might identify markers and improve the knowledge of the underlying neurobiology of 
psychosis and schizophrenia. And therefore, the hippocampus and its network are the 
brain region, which should be further investigated. Moreover, replication studies are 
needed and should be further validated by meta-analytic procedures. 
4.4 Outlook 
First, as we could show differences in hippocampal volumes in our studies, I suggest 
further investigation of the interrelated neuronal connections of the hippocampus, 
especially to the PFC, as the disconnectivity hypothesis by Friston and Frith (Friston 
and Frith, 1995) proposes. Furthermore, the molecular biology behind this connection 
should be further evaluated for a better neurobiological understanding of this 
disorder. Such a potential molecular pathway modulating hippocampal-PFC 
connectivity might involve aberrant glutamatergic neurotransmission and calcium 
signaling, both influencing synaptic plasticity, thus cognition (Kandel, 2012; 
Miyamoto, 2006; Rao and Finkbeiner, 2007). Moreover, whole genome sequencing 
will allow the application of genetic analysis to large samples, which will increase the 
identification of schizophrenia candidate variants. And growing collaborations and 
the formation of consortia are therefore another important factor to increase power in 
psychiatric research to gain new insight. Together the identification of potentially 
impaired genetic markers might then also allow the design of new drugs to fitted 
targets. 
Second, a tool for investigation of the diagnostic outcome is machine learning. 
Supervised learning is the categorization of complex, high dimensional training data 
and applying the learned classification rules to new data. Several studies could show 
with automatic pattern classification that structural (Borgwardt et al., 2013; 
Koutsouleris et al., 2015, 2012, 2009) or functional (Modinos et al., 2013, 2012) 
neuroimaging markers can classify ARMS individuals and FEP patients from HC. 
Moreover, machine learning allowed the prediction of transition to psychosis with up 
to 88% accuracy based solely on structural neuroimaging markers (Borgwardt et al., 
2013; Koutsouleris et al., 2015, 2012, 2009). In contrast, only one study used genetic 




discrimination of FEP patients from HC at the individual level. However, clinical 
high-risk individuals could not be separated from FEP patients or HC (Pettersson-
Yeo et al., 2013). We are planning to incorporate longitudinal data (demographic, 
clinical, cognitive, genetic and neuroimaging) into a multivariate machine learning 
analysis, which might increase the accuracy to separate ARMS individuals with 
subsequent transition to psychosis from ARMS individuals that do no transition and 
FEP patients that develop chronic schizophrenia from those with only one episode. 
This might help to identify relevant biological markers, which might then finally be 
used for personalised diagnostics applied in clinical psychiatric practice. 
Third, this knowledge of new biomarkers can then be further used for better 
diagnostics across neuropsychiatric disorders. Several studies showed the high 
genetic similarity of shared risk alleles between neuropsychiatric disorders, especially 
the genetic relationship between bipolar disorder and schizophrenia (Cross-Disorder 
Group of the Psychiatric Genomics Consortium, 2013; Cross-Disorder Group of the 
Psychiatric Genomics Consortium et al., 2013; Ruderfer et al., 2014; Tesli et al., 
2014). The high overlapping risk variants of bipolar disorder and schizophrenia in 
symptomatology stands in favor of the psychosis continuum model. Therefore, it may 
be necessary to revise psychiatric nosology. One suggestion supporting the idea of a 
disease continuum in psychiatry was made by the Research Domain Criteria (RDoC) 
(Cuthbert and Insel, 2013; Insel et al., 2010) initiative. They proposed to classify 
neuropsychiatric disorders according to dimensions of neurobiology and observable 
behaviour. In detail these are the positive and negative valence system, the cognitive 
system, systems for social processes and the arousal/modulatory system. But before a 
new diagnostic system can be considered, we need a better understanding of the 
neurobiology underlying neuropsychiatric disorders. For this aim, the transition of 
ARMS individuals to either schizophrenic or affective psychosis makes the ARMS a 
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